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Introduction: Sodium hemostasis is altered in patients with chronic kidney disease (CKD) 
due to long term loading, and sodium (23Na) can be deposited in the skin, muscle and 
skeleton. We measured 23Na content in these tissues of CKD patients, using 23Na magnetic 
resonance (MR) imaging. 
Methods: This is a pilot cross-sectional study of CKD stage 4-5D patients and controls with 
normal kidney function. Subjects underwent a 23Na MR study of their right lower leg using a 
multinuclear-capable 3.0-T MRI. An axial proton T1-weighted fast-low-angle-shot sequence 
was acquired to delineate the anatomy; followed by a 23Na MR image obtained with a 
custom-made 23Na coil and sodium-optimized pulse sequences. Concentration maps were 
generated using saline solutions at different 23Na concentrations as calibration vials. Four 
regions of interest (ROIs) were drawn: 1) pre-tibial skin, 2) posterior leg skin, 3) tibia, and 4) 
soleus muscle. Baseline characteristics and blood samples were also collected.  
Results: 10 controls, 12 CKD and 23 dialysis (10 peritoneal dialysis (PD) and 13 
hemodialysis (HD)) subjects participated in the study. 23Na concentration in all four tissues 
was significantly higher in dialysis patients compared to controls (p-value <0.05). No 
significant difference was found in the tissue 23Na of HD, PD and CKD groups. Tissue 
sodium levels correlated strongly with markers of mineral bone disease and inflammation. 
Associated factors appear to be tissue specific.  
Conclusion: Dialysis patients were found to have significantly higher 23Na level in their 
tissues compared to controls with normal kidney function. The effect and clinical utility of 
tissue 23Na remains to be studied. 
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Introduction: Introduction: When the kidney malfunctions, individuals cannot excrete 
sodium. This results in the deposition of sodium in the skin, muscle and bones, especially in 
patients who require dialysis because of minimal kidney function. We used magnetic 
resonance technology to study the amount of sodium in these tissues of patients with kidney 
disease. 
Methods: We studied 10 healthy individuals, 12 patients with kidney disease not on dialysis 
and 23 dialysis patients (13 on hemodialysis and 10 on peritoneal dialysis - the two most 
common types of dialysis). Each subject was brought in for a study visit, where we collected 
their medical history and blood samples, and obtained a cross-sectional image of their R leg. 
The image was taken with a modified magnetic resonance scanner which detects sodium 
content. We had vials with known sodium concentration included in the image, to calibrate 
the level of sodium in the different regions. Four regions of interest were drawn over the 
image: over the soleus muscle, the bone, and two areas of the skin (the skin over the shin and 
from the back of the calf) - to highlight the different tissues. 
Results: Sodium levels in all four areas (three tissues) were higher in dialysis patients 
compared to healthy individuals. We did not find a difference between patients on peritoneal 
dialysis, hemodialysis, or not on dialysis yet. Higher sodium levels in the muscle and bone 
were associated with increased inflammation, as well as other markers of kidney disease. The 
sodium levels in the different tissues were associated with different factors. 
Conclusions: Dialysis patients have higher sodium levels in their skin, muscle and bone, 
compared to healthy individuals. The mechanism of sodium storage and its effect on 
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Chapter 1  
1 Background 
This chapter provides some background information about the work described in the 
following chapters. This includes descriptions of the Kidney (in Health and Disease) (Section 
1.1), Current Knowledge of Sodium Metabolism (Section 1.2), 1H Magnetic Resonance Imaging 
(Section 1.3), and 23Na Magnetic Resonance Imaging (Section 1.4). 
 
1.1 The Kidney – in Health and Disease  
The kidney is a vital organ with several key functionalities. This section highlights the 
anatomy and physiological function of the kidney, as well as definitions of CKD and renal 
replacement therapies. A further in-depth description of the kidney and its role can be found in 
multiple textbooks. [1-5] 
 
1.1.1 Kidney Anatomy 
The kidneys are bean shaped organs, weighting on average about 150 g each, and located 
in the retroperitoneum. In total, they receive approximately 20% of the cardiac output, which is 
distributed through the ~2 millions of nephrons – the functional units of the kidneys (Fig. 1-1). 
[1-5] The nephron is composed of two main parts: the glomerulus and the tubules, and is 
surrounded by a set of arterioles, capillaries and venules. Blood is initially filtered through the 
glomerulus, producing ultra-filtrate - an acellular aqueous solution with plasma-like contents 
(except for macromolecules). The contents of this ultra-filtrate are then modified by the 
absorption and secretory function of the different parts of the tubule to produce the end-result: 










1.1.2 Kidney Function 
The functions of the kidney include: 
- Maintaining the body composition of water and electrolytes: The kidney regulates the 
composition of the fluid in the body and its osmolytes. Using a series of feedback 
mechanisms, the amount of water and other electrolytes that the kidneys excrete in the 
urine are highly adaptable. As such, the kidney plays an important role in regulating the 
body content of water, sodium, potassium, chloride, bicarbonate, calcium, magnesium 
and phosphate. This role of the kidney is quite crucial since most cellular enzymatic 
processes and electrochemical gradients rely on the tight regulation of these ionic 
concentrations.      
- Excreting metabolic waste products and foreign substances: A number of end-products 
and toxins are produced during physiological and pathological processes in the body, 
which are cleared by the kidneys. This includes urea, creatinine, acids and drugs.  
Figure 1-1: A) The kidney with its renal artery and vein, and ureter for urine output; B) The 
nephron – the functional unit of the kidney. It has two main sections: the glomerulus and the 















- Production of hormones: 
o Renin: In response to renal blood flow, the kidneys will release renin – a hormone 
which catalyzes the formation of Angiotensin II – a potent vasoconstrictor. 
Angiotensin II not only causes significant changes in peripheral vascular 
resistance, but also has direct and indirect effects in the tubular reabsorption of 
sodium and water through its effect on renal vasculature and aldosterone 
production by the adrenal glands. Through these mechanisms, the kidneys play a 
key role in blood pressure regulation and hemodynamic stability. 
o Erythropoietin: The kidney is the main site for production of erythropoietin – a 
hormone that is key in stimulating the production of erythrocytes (or red blood 
cells) in the bone marrow.  
o 1,25-Dihydroxyvitamin D: Kidneys are needed to activate vitamin D into its 
active metabolite 1,25-dihydroxyvitamin D. This active metabolite then helps 
regulate body calcium and phosphate levels, as well as having feedback roles on 
parathyroid hormone and bone metabolism.  
 
1.1.3 Chronic Kidney Disease  
CKD is defined by the Kidney Disease Improving Global Outcomes (KDIGO) guideline 
as “abnormalities of kidney structure or function, present for >3months, with implication for 
health”. [6] Even so, this condition describes a wide range of diseases that can affect the kidney 
and has significant variations in severity. As such, KDIGO further classifies CKD in stages 1-5 
(Table 1-1), based on the glomerular filtration rate (GFR). [6] Patients who are on dialysis are 
often classified as CKD 5D, to differentiate them from CKD 5 – not on dialysis. GFR is 
estimated based on serum creatinine (a molecule readily filtered in the glomerulus). [7] 
The prevalence of CKD stages 1-5 is approximately 13.4% of the general population, 
while stages 3-5 is 10.6%. [8] Patients with CKD are at increased risk of morbidity and mortality 
– particularly cardiovascular mortality. The risk of hospitalization and cardiovascular events 
progressively increases as GFR declines. [9] Survival rates for dialysis patients at one, two and 
five years are approximately 81, 65, and 34%, respectively. [10] As such, due to its high 





Table 1-1: Description of the Stages of CKD, from mild (Stage 1) to severe (Stage 5) [6] 
Stage GFR (ml/min/1.73 m2) Description 
Stage 1 >89 Normal or high 
Stage 2 60-89 Mildly decreased 
Stage 3a 45-59 Mild-moderately decreased 
Stage 3b 30-44 Moderate-severely decreased 
Stage 4 15-29 Severely decreased 
Stage 5 <15 Kidney Failure 
 
 
1.1.4 Renal Replacement Therapies  
When the kidney function has decreased to a level incompatible with a functional life, 
patients tend to have two main options with regards to renal replacement therapies: dialysis – 
either hemodialysis or peritoneal dialysis, or kidney transplantation. Furthermore, hemodialysis 
is sub-categorized into in-center hemodialysis – where patients come to a medical facility three 
times a week for 3-4 hours to have their treatments, or home hemodialysis – where the patients 
are trained to do their own treatment in a home setting.  
For the purpose of this thesis, the following sections provide information on the two renal 
replacement therapies relevant to this study: in-center hemodialysis and peritoneal dialysis. More 
in-depth discussion can be found in the references. [2-4,12-14] 
Dialysis is a poor approximation of the kidneys – in that it helps remove particles (for e.g. 
electrolytes, end products of metabolism, and drugs) and excess water from the body, but its 
performance falls short of the full functionality of the kidneys. The dialysis apparatus requires 
three main components: access to blood or fluid compartment in the body, a semi-permeable 
membrane and dialysate fluid. Particles (or solutes) and water mostly cross the semi-permeable 




which diffuse into the blood). In general, two different processes occur simultaneously during 
dialysis: 1) solute clearance and 2) ultrafiltration. Solute clearance refers to the clearance of 
solutes via diffusion, while ultrafiltration is the removal of fluid – via hydrostatic or osmotic 
pressures. Ultrafiltration does result in some removal of solutes, since water will often drag 
solutes via solvent drag across the semi-permeable membrane. 
 
1.1.4.1 In-Center Hemodialysis 
Hemodialysis is a process where blood is taken from a patient’s vessels, run through a 
hemodialysis filter (Fig. 1-2) to adjust its composition, before it is returned back to the patient’s 
vasculature. Inside the filter, blood runs counter-parallel to the dialysate fluid, separated through 
a polymeric membrane. The counter-parallel flow is integrated to ensure maximal solute 
clearance by maintaining concentration gradients throughout the filter length. Ultrafiltration rates 
can be adjusted by applying negative hydrostatic pressure to the dialysate compartment of the 















In-center HD is the outpatient delivery of hemodialysis treatments in hemodialysis units. 
Patients come to these units usually three times a week, for 3 to 4 hour-long hemodialysis 
treatments. The HD machine is set up, monitored and adjusted by trained health care 
Hemodialysis Filter 
Figure 1-2: Schematic representation of the hemodialysis apparatus: depicting 
blood and dialysate counter current flows within the hemodialysis filter, the 





professionals, who also closely observe the patients for complications. Since this is the only 
dialysis modality that has trained professionals available for the entire treatment, in-center HD 
patients tend to have lower health status and higher levels of comorbidities compared to those on 
other dialysis modalities.  
 
1.1.4.2 Peritoneal Dialysis 
Peritoneal dialysis involves the transport of solutes and water across the peritoneal 
membrane, which serves as the semipermeable membrane between the blood in the peritoneal 
capillaries and the dialysis fluid in the peritoneal cavity. Dialysate solution is infused into the 
abdomen of patients and allowed to dwell there for a set period of time (varies from 1 to over 16 
hours). The transport of solutes and water between the dialysate solution and blood occurs during 
this dwelling time. For solutes, this transport is dependent on concentration gradients, osmotic 
and oncotic pressures (since water transports affects solute movements through convection or 
solvent drag), as well as the pore sizes in the peritoneal membrane (which acts as a filter). Water 
movement depends on the oncotic and osmotic pressures. Initially these pressures are set by 
adding dextrose or other polymers to the dialysate fluid, but with time they adapt with the 
diffusion of solutes (in and out of the peritoneal space). Overall, with longer dwell times the 
concentration of solutes (like toxins, urea, phosphate etc.) in the dialysate fluid equilibrates with 
that of blood. Generally, patients undergo PD for at least 8 hours, with anywhere from 1-7 dwells 
a day. As such, PD prescriptions are highly adjustable.   
In contrast to HD, PD tends to be less efficient with respect to solute clearances. Even so, 
PD does have some advantages. First, it is less expensive than traditional in-center HD. [15-17] 
Second, PD is associated with better health related quality of life. [18,19] This dialysis is done at 
home by the patients or their caregivers, allowing patients the freedom, flexibility and control to 
perform their own treatment regimen and facilitate their return to everyday activities. Lastly, PD 
has been found to have an early survival advantage compared to in-center HD – attributed to 





1.1.5 Complications of CKD 
CKD results in a number of biochemical abnormalities and complications. [1-4,6,12] 
These complications become more severe as CKD progresses to later stages (stage 5). Only some 
of them are treated with dialysis. 
o Uremia: As kidney function deteriorates, the ability of the kidney to excrete 
metabolic end-products and toxins decreases. This results in an accumulation of these 
compounds – including creatinine and urea (readily measured in plasma in clinical 
practice) and other unmeasured non-protein nitrogen compounds. Build-up of these 
toxins past a critical threshold (which is patient-specific) results in a series of non-
specific symptoms collectively known as “uremic symptoms”. Uremic symptoms 
include nausea and vomiting, decrease appetite, pruritus (itch), lethargy, confusion 
and decreased level of consciousness, and chest pain from uremic pericarditis. The 
presence of these symptoms indicate the need to initiate renal replacement therapy, 
otherwise the individual will die as a result of their kidney disease.   
o Hyperkalemia: As CKD progresses, the excretion of potassium in the urine is 
impaired, resulting in hyperkalemia, a dangerous condition which can result in fatal 
cardiac arrhythmias. Hyperkalemia is treated with two main approaches: 1) 
Decreased intake through low-potassium diet and potassium-binding resins to reduce 
potassium absorption in the gastrointestinal tract; 2) Increased excretion through 
diuretics (to increase excretion from the native kidneys) and renal replacement 
therapies – the latter as a last resort.  
o Acidosis: The kidneys ability to re-absorb and produce bicarbonate is compromised 
in CKD, resulting in the build-up of acid components produced by metabolism. 
Treatment of acidosis involves supplementation with sodium bicarbonate or renal 
replacement therapy.  
o Anemia: CKD (usually stages 4-5) often results in anemia. The mechanism through 
which CKD causes anemia is multifactorial. First, as its function deteriorates, the 
kidney releases less erythropoietin into the blood stream – a hormone that is needed 
for erythrocyte production in the bone marrow. Second, absorption of iron (a key 
element in hemoglobin) from the gastrointestinal tract is diminished in these patients.  




which diminishes its normal activity. Anemia is often treated in CKD by 
supplemental iron (oral or intravenous), erythropoietin stimulating agents, and (if 
needed) dialysis to increase clearance of toxins.  
o Mineral Bone Disease (MBD)– As kidney function diminishes, the kidneys are 
unable to re-absorb calcium, secrete phosphate and activate Vitamin D to 1,25-
dihydroxy-Vitamin D. These changes in calcium/phosphate homeostasis result in 
secondary and eventually tertiary hyperparathyroidism (increased parathyroid 
hormone- PTH), and osteomalacia and other metabolic bone diseases. Dysregulation 
of the mineral bone disease markers has also been associated with increased 
mortality, and vascular disease from extra-skeletal calcification in vessels. Current 
treatment includes adhering to a low-phosphate diet, phosphate binders to decrease 
phosphate absorption, calcimimetic agents – to trick the parathyroid gland that the 
body is hypercalcemic, administration of active vitamin D compounds, and renal 
replacement therapies. With regards to the latter, aside for transplantation, dialysis is 
limited in phosphate removal – since the majority of this anion is intracellularly 
stored, and thus, not readily accessible with dialysis.   
o Water and Sodium Retention, and Blood Pressure: As CKD progresses, the residual 
renal function decreases, and thus, smaller volumes of urine are excreted. These 
smaller urine volumes result in less water and sodium excretion, and consequently, 
increased total body fluid and total body sodium content. Clinically, this manifests as 
signs and symptoms of volume overload and hypertension. Patients are advised to 
decrease their sodium and water intake. In addition, attempts are made to increase 
residual renal function with the use of diuretics, and once medical therapy fails, with 
renal replacement therapy. Lastly, sometimes paradoxically, as CKD progresses the 
kidney releases more renin, causing significant vaso-constriction and hypertension 
though activation of Angiotensin II.  
o Cardiovascular: CKD patients are at increased risk for cardiovascular disease and 
mortality. [9, 22,23] This risk has been attributed to a higher prevalence of traditional 
risk factors (e.g. hypertension, diabetes, left ventricular hypertrophy, smoking, 
sedentary lifestyle, etc.), as well as non-traditional factors like chronic volume 




cardiac injury, is often elevated in CKD patients – partially due to its decreased 
clearance. Even so, chronically elevated troponin levels are associated with worse 
prognosis in CKD. [24,25]  
o Inflammation: CKD and dialysis are also associated with recurrent and chronic 
inflammatory processes. [26-31] These patients often have low albumin and 
hemoglobin, and high C-reactive protein (CRP) levels, indicative of inflammation. 
The etiology of inflammation is believed to be multifactorial including elevated pro-




1.2 Current Knowledge of Sodium Metabolism 
This section provides a brief overview of current teaching on sodium handling by the 
body. Sodium metabolism has been previously described in multiple other sources. [1-5] The 
main principle in sodium balance physiology postulates that sodium content is conserved in 
steady-state: 
 
Sodium Intake = Sodium Excretion    [1.1] 
 
Since a large portion of the total sodium content is in aqueous solution, this section also contains 
a brief explanation of the fluid compartments in the body.  
 
1.2.1 Fluid Compartments  
The total body water (TBW) is compartmentalized into intracellular fluid (ICF = ~2/3 of 
TBW) and extracellular fluid (ECF = ~1/3 of TBW) (Fig. 1-3). These two compartments are 
separated by the cell membrane. ECF is further divided into interstitial fluid (ISF), which bathes 
all the cellular components in tissues, and plasma fluid (PF) – separated by the capillary wall. 
The concentrations of the main cations and anions in the PF and ICF are highlighted in Table 1-
2. Since these electrolytes freely permeate the capillary wall, PF concentrations are generally 
assumed to be representative of ECF content. This assumption is not completely accurate, since 
the protein composition (specifically albumin) of PF and interstitial fluid are different. Albumin 
is negatively charged and attracts cations, thus distorting their concentration slightly in its 
vicinity – a phenomenon called the Gibbs-Donnan effect. Since albumin levels are higher 











Figure 1-3: Estimates of major body fluid compartments with respect to body weight and 




Table 1-2: Typical ionic composition of plasm and intracellular fluid (adapted from [1,4]) 
Constituent Blood Plasma (mmol/L) Intracellular fluid (mmol/L) 
Sodium (Na+) 143 12 
Potassium (K+) 4 150 
Chloride (Cl-) 104 4 
Bicarbonate (HCO3
-) 24 10 
 
 
1.2.2 Sodium Intake  
In industrialized countries, average sodium intake is 100-200 mmol/day (~2-4 grams/day) 
[29,30]. Since humans can survive and function normally on 10-20 mmol/day, current sodium 
intake is almost always greater than the amount necessary for homeostasis. Yet, salt appetite is 
often independent of salt-repletion. However, sodium-deplete states – often perceived as 
Total Body Water (TBW) 
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Intracellular Fluid (ICF) 
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decreased blood volume, low blood pressure, or decreased extracellular fluid sodium 
concentration – are significant stimuli for both sodium appetite and water thirst.  
 
1.2.3 Sodium Excretion 
The sodium balance equation [1.1] translates a precisely balanced sodium and water 
intake with their excretion, in order to keep the size of the ECF constant. Sodium loss is 
dependent on three main mechanisms: losses through sweat and the gastrointestinal tract – which 
are not regulated, and renal losses which are. Sodium excretion by the kidney is subject to 1) 
ultrafiltration in the glomerulus, and 2) reabsorption in the tubule. Sodium is not secreted in 
urine. Since sweat and gastrointestinal losses are minimal (less than 5mmol/day and 
approximately 10mmol/day, respectively) in regular conditions (room air, regular activity and 
normal bowel movements), [32] the following explanation on the regulatory mechanism of 
sodium excretion is focused on renal losses.  
 Since sodium is the most abundant extracellular cation, it is a key osmolyte regulating the 
ECF volume, and thus, effective circulatory volume (through PF) and blood pressure. As such, 
any fluctuations in total body sodium results in concurrent fluctuations in ECF volume. In 
response, a number of regulatory feedback mechanisms are activated (Fig. 1-4, described in 
multiple textbooks [1-5]):  
- Sympathetic Nervous System (SNS): fluctuations in the ECF volume are readily detected 
by stretch and baro-receptors in the blood vessels. If ECF volume is low, these receptors 
will activate the sympathetic nervous system. Increased sympathetic activity increases 
renal arteriole vasoconstriction – decreasing GFR and ultrafiltration, and enhances renal 
salt reabsorption in the tubule.  
- Renin-Angiotensin-Aldosterone System: Renin release by the kidneys is triggered by low 
intravascular fluid volumes (detected as decreased tubular flows), baroreceptor 
stimulation and direct adrenergic activity (sympathetic nervous system). Renin catalyzes 
the activation of Angiotensin II, a potent vasoconstrictor. Similar to the sympathetic 
activity, Angiotensin II decreases sodium excretion by affecting both ultrafiltration (by 
decreasing GFR) and directly enhancing sodium reabsorption in the proximal tubule. In 
addition, Angiotensin II stimulates the production and release of aldosterone from the 




the nephron) to increase the activity of epithelial sodium channel, ENaC, to reabsorb 
more sodium and excrete potassium.  
- Urodilatin, Uroguanylin/guanylin, Atrial Natriuretic Peptide (ANP) and Brain Natriuretic 
Peptide (BNP): Multiple organs have their own hormone peptides to help adjust sodium 
(and subsequently water) content in the body. ANP and BNP are peptides produced by 
atrial and ventricular myocytes, respectively, in conditions of increased cardiac stretching 
– or volume expansion. Urodilatin is produced by the kidneys, and uroguanylin/guanylin 
are produced by the gastrointestinal tract in response to oral ingestion of sodium. All 
these peptides induce natriuresis (or excretion of sodium) along the nephron tubule.    
- Increased Cardiac Output: Increased cardiac output results in vasodilation of the renal 
arterioles, increasing GFR and thus ultrafiltration and ultimately loss of sodium.   
- Tubulo-glomerular Feedback: Changes in the GFR can be induced in the kidney by local 
feedback mechanism from the flow rate and content of ultrafiltrate in the tubules. These 
ultrafiltrate factors result in changes in the Starling forces via hydrostatic and oncotic 
pressures that are detected by the tubules. Changes in these factors initiate a negative 
feedback that serves to restore normal Starling forces in the tubule.  
- Water Reabsorption and Antidiuretic Hormone (ADH): Since sodium and water balances 
are quite closely interconnected, water reabsorption in the kidneys also plays a role. 
Water reabsorption is mostly controlled by osmoreceptors in the brain which detect 
changes in plasma osmolality. When this osmolality is increased, ADH is produced, a 
hormone that stimulates free water absorption in the kidney. Furthermore, ADH is 
stimulated by decreased circulatory volume, with the aim of restoring it. Thus, ADH 
indirectly affects sodium metabolism, by its effect on the circulatory volume.  
Through these mechanisms, sodium excretion by the kidney can fluctuate from virtually zero, to 






























1.2.4 Sodium in Disease  
A high salt diet has been implicated in a number of diseases including hypertension, 
glucose intolerance, cardiovascular disease, progression of CKD, autoimmune conditions and 
even cancer. [34-43] Such diets also interfere with treatments – for example high salt diets make 
anti-hypertensive drugs less effective, and trigger episodes of congestive heart failure (CHF). 
Figure 1-4: Key players in regulating effective circulating volume and sodium excretion by 
the kidneys. CNS- Central nervous system, ADH – anti-diuretic hormone, ANP – Atrial 
natriuretic peptide. Adapted from [34] 
Decreased Effective Circulating Volume 
Altered Renal Tubule Transport and Hemodynamics 

























Given that sodium excretion is mostly a renal process, it is believed that dysregulation in the 
kidney function contributes to sodium retention and consequently disease.  More specifically, in 
hypertension, the kidney is believed to have an inherent inclination toward sodium and water 
retention, which reset the pressure natriuresis (i.e. higher blood pressures are needed to excrete 
the steady state sodium intake).  
In CKD and dialysis patients, sodium excretion is impaired. 24-hour urine collections of 
CKD patients show decreasing sodium excretion with advancing CKD. [43] This is particularly 
important for dialysis patients, who often have negligible urine outputs. As such, these patients 
are at increased risk of sodium loading – especially in between their dialysis sessions (usually 
hours for PD, and up to 3 days for HD). Dialysis does remove sodium, yet sodium removal 
patterns are hardly physiological due to their intermittent pattern, especially for hemodialysis 
(due to its short intra-dialytic and long inter-dialytic times). [42-44] Thus, this population may be 
quite vulnerable to salt-related pathophysiological changes.  
 
1.2.5 Sodium in CKD  
CKD is comprised of a large group of heterogeneous pathophysiological conditions. As 
such, depending on the exact mechanism and severity, the effect on sodium hemostasis can be 
variable. The mechanism of CKD progression and its effect on sodium balance has been 
discussed in detail in previous literature. [1-5,12] This section provides a brief summary.  
Patients with CKD can experience both sodium retention and sodium depletion. The 
latter is less common and often a consequence of tubulo-interstitial disorders (affecting the 
tubules and interstitial space). In these conditions, the tubule loses its ability to re-absorb sodium, 
which results in high sodium losses in the urine. Glomerular diseases are more common and 
result in increased sodium retention.  
If a critical number of nephrons is damaged, the remaining nephrons will be exposed to 
increased blood flow and compensate by hypertrophying and increasing their GFR. While these 
adaptive changes are beneficial in the short term, in the long term they result in glomerular injury 
and increase proteinuria (leaking of protein into the urine). Furthermore, increased Angiotensin 
II local cytokine activity cause inflammation and fibrosis of the glomerulus and the vessels. 
Glomerular scarring decreases the ultrafiltration in the glomeruli, while Angiotensin II increases 




In CKD, in order to try to maintain a neutral sodium balance, patients are often 
prescribed low salt diets (less than 2g of sodium a day) and diuretics. These medications work by 
decreasing sodium re-absorption in different parts of the tubule, and thus increasing the sodium 
loss from the functioning nephrons.  
 
1.2.5.1 Sodium in Dialysis  
Sodium excretion in dialysis patients consist of the cumulative losses from dialysis and 
residual renal function (equation [1.2]). These patients often have minimal residual renal 
function, and thus need to rely on the clearance and ultrafiltration processes of dialysis to excrete 
most of their sodium intake (equation [1.3]). Sodium handling during dialysis has been 
previously outlined in the literature [12,34,46,47] 
 
 Sodium Losses = Renal Sodium Excretion + Dialysis Sodium Removal  [1.2]  
  
Dialysis Sodium Removal = Diffusive Removal + Ultrafiltration Removal  [1.3] 
 
For in-center HD, sodium removal is dependent primary on ultrafiltration through 
convective losses (~78%), rather than clearance through diffusive losses (~22%). [48] As fluid is 
pulled from the body, it drags with it sodium – a phenomenon called “solvent drag”. The sodium 
concentration in the ultrafiltrate is slightly lower than that of plasma due to the Gibbs-Donnan 
effect of proteins (i.e. the effect of the negatively charged proteins on this positive cation, as 
explained in Section 1.2.1). Thus, sodium removal with ultrafiltration depends primarily on the 
amount of fluid removal (i.e. if HD removes 2L of fluid with a plasma concentration of 
140mmol/L, this results in a bit less than 280mmol of sodium removal with ultrafiltration). 
Diffusive losses of sodium serve to fine tune the sodium balance in these patients. Yet, not all 
plasma sodium is available for diffusion. The easily diffusible sodium is dissolved in the aqueous 
component of plasma, unbound to other molecules. The diffusion process is dependent on the 
concentration gradient between plasma sodium and dialysate sodium. This latter parameter can 
be adjusted in the HD machine (in the range of 132-155mmol/L) for each patient. Thus, diffusive 
losses are variable and depend on the difference between the set dialysate sodium concentration 




Since the 1980s, dialysis units adopted a higher sodium concentration in the dialysate, 
since it reduces intra-dialytic hypotension and increases patient tolerance of the HD process. [50] 
This often results in dialysate sodium concentration which are higher than plasma sodium ones; 
and thus, a diffusive influx of sodium into the body. In general, post HD plasma sodium exceeds 
pre-HD levels by 2-4mmol/L – implying that total losses during dialysis are hyponatremic.(i.e. 
the concentration of sodium in the fluid losses during dialysis is lower than that of plasma) [50] 
Unfortunately, this approach can result in lower sodium removal compared to intake, and thus 
sodium accumulation in the body. Higher dialysate sodium is associated with increased inter-
dialytic weight gains and higher blood pressures in patients. [51] In addition, while sodium 
removal in HD can be increased by rising ultrafiltration rates, there are clinical limitations to the 
amount of fluid removed due to patient symptoms. Furthermore, increased ultrafiltration rates are 
associated with hemodynamic disequilibrium and organ dysfunction. [52-58] 
Equations [1.2] and [1.3] also apply to peritoneal dialysis. In contrast, the dialysate 
sodium concentration in PD is usually set at 132mmol/L (dialysate fluid bags used in North 
America come pre-packaged at this concentration). When dialysate is infused into the abdomen, 
the high osmolality from its carbohydrate content causes an influx of water. This water influx 
drags along some sodium cations through solvent drag. This ultrafiltrate fluid has slightly lower 
sodium concentration than plasma (due to the Gibbs-Donnan effect) and results in an initial 
decrease in the sodium concentration in the peritoneal fluid. [59] While the sodium concentration 
is lower, total sodium content is higher due to the increased volume of fluid. As the fluid is left 
to dwell in the peritoneal space, the sodium concentration rises toward plasma sodium levels due 
to diffusion. Yet, the osmotic gradient is usually slowly lost when the dialysate contains simple 
carbohydrates which are easily absorbed. The loss of the osmotic gradient decreases the dialysate 
volume. As such, depending on the initial osmotic gradient, dwell time and the rate of osmotic 
gradient loss (dependent on the properties of the peritoneal membrane), the amount of sodium 
and fluid removal is variable. In order to adjust sodium and fluid removal several parameters can 
be adjusted: the initial osmotic gradient, dwell time and number of cycles. Even so, increasing 
osmotic gradient by adding more carbohydrate results in significant metabolic consequences 
(e.g. insulin resistance) and damage to the peritoneal membrane. Lastly, dialysis solutions exist 




and oncotic pressures, but these solutions have only been studied as single dwell solutions over 
24 hours (i.e. they are only used for one dwell a day).      
The majority of sodium removal in PD, similar to HD, occurs due to ultrafiltration 
(removal of sodium from fluid removal), as opposed to diffusion. [60] Attempts have been made 
to increase sodium removal via lowering dialysate sodium concentration in this modality to 
increase sodium removal with mixed results. [61-64] 
Thus, both dialysis modalities remove sodium mostly through ultrafiltration, with some 
contribution from diffusion. Different parameters can be adapted to increase sodium removal, but 









1.3 1H Magnetic Resonance Imaging  
This section provides general information about the principles of magnetic resonance 
imaging (MRI). Further details about this technology can be found in several references. [65-68] 
MRI is an imaging modality that utilizes the magnetic properties of nuclei to develop 
images of tissues and structures. This technology is used extensively in the medical field to form 
3-dimensional images of the anatomy and the physiological processes of the body with un-
paralleled soft tissue contrast. Furthermore, it can detect pathological changes in tissues and thus, 
help diagnose medical conditions.  
In this modality, patients are placed in a strong homogenous magnetic field (1.5-3.0 T in 
clinical systems) generated by superconducting magnets. The temperature of these magnets is 
maintained near absolute zero (4.2 K) by liquid helium to eliminate electrical resistance in their 
windings. This sustains a large persistent electrical current in the magnet and a commensurate 
magnetic field within the MRI system. 
 
1.3.1 Nuclear Spin and the Effect of External Magnetic Fields  
In principle, any nucleus with an odd number of protons or neutrons can be detected with 
magnetic resonance. Biologically relevant nuclei include 1H, 13C, 15N, 17O, 19F, 23Na and 31P. 
Compared with other imaging modalities MRI has an intrinsically limited sensitivity and in-vivo 
MRI is typically restricted to 1H imaging due to its high tissue concentration and high sensitivity 
for MR. Protons (1H) have a nuclear spin, I = ½. The strength of their interaction with magnetic 
fields is determined by their magnetic dipole moment, 𝜇 given by 
 
𝜇 = 𝛾𝐼        [1.4] 
 
where 𝛾 is known as the gyromagnetic ratio. The signal in MRI scales as 𝛾3and the 
gyromagnetic ratio for protons is 42.576 MHz/T, which is the largest value for any nucleus. 
When water-associated protons in tissue are placed in a magnetic field, 𝐵0, their magnetic dipole 
moments precess around the magnetic field direction (Fig. 1-5) at the Larmor frequency, 𝜔0 
given by: 





Under normal conditions at body temperature there is a small preference for the cone of 
precession to be oriented in the direction of the magnetic field. This leads to a net magnetization, 
(𝑀0⃗⃗ ⃗⃗  ⃗) of the protons and hence the tissue. The amount of magnetization, M0 is dependent on the 
concentration and magnetic dipole moment of the protons as well as the temperature of the 














Figure 1-5: Dipoles in an external magnetic field B0: A) Alignment of the dipoles with the 
magnetic field in the parallel or anti-parallel directions, and B) Processing of the dipole at 
Larmor frequency around the axis of the external magnetic field B0. Adapted from [65]    
 
 
MRI imaging works by perturbing the direction of the 𝑀0⃗⃗ ⃗⃗  ⃗ vector away from 𝐵0⃗⃗⃗⃗  by 
applying a brief radiofrequency (RF) pulse (creating a time-varying 𝐵1⃗⃗⃗⃗  magnetic field at the 
Larmor frequency in a direction perpendicular to 𝐵0⃗⃗⃗⃗ ). The magnitude of 𝐵1⃗⃗⃗⃗  is much weaker than 
that of 𝐵0⃗⃗⃗⃗ , on the order of 50 T. This produces a transverse magnetization, ?⃗⃗? 𝑡, which precesses 
around the magnetic field, 𝐵0⃗⃗⃗⃗ , (whose direction is conventionally assumed to be along the z-axis) 
in the xy plane at the Larmor frequency. This is depicted in Fig. 1-6.  The initial amplitude of ?⃗⃗? 𝑡 
is determined by the duration and amplitude of the RF pulse quantified by a quantity known as 
the flip angle, , which can range from a few to 90 degrees. After the RF pulse is turned off, the 
amplitude of the transverse magnetization, ?⃗⃗? 𝑡  decays as the z-component of the longitudinal 
magnetization, 𝑀𝑧 regrows. This asymptotic regrowth of the longitudinal magnetization is 
known as spin-lattice relaxation, which is governed by the spin-lattice relaxation time constant T1 
as described by equation [1.6]: 






 𝑀𝑧(𝑡) = 𝑀0(1 − 𝑒
−𝑡
𝑇1
⁄ )      [1.6] 
 
T1 is known as the spin-lattice relaxation time because it is indicative of the time needed 
for the nuclei to lose the energy absorbed from the RF pulse into the surrounding lattice to 






















Prior to the RF pulse, the magnitude of the transverse magnetization, Mt is zero, and after 














Figure 1-6: The initial effect of the RF pulse B1 on the magnetization vector of the tissues 
M0. Initially M0 is flipped from the z-axis, with a flip angle , and has two components: 




T2 is the transverse relaxation time (also known as the spin-spin relaxation time) and is due to 
dephasing of individual nuclear spins while precessing in the xy plane. This dephasing is a result 
of the interactions of the spins with each other. In practice, the effective relaxation time (𝑇2
∗) is 
actually shorter than that predicted by natural atomic and molecular mechanisms due to external 
field inhomogeneities The external magnetic field  𝐵0⃗⃗⃗⃗  produced by the superconducting magnet 
is not strictly uniform, and even though shim coils are employed to increase uniformity, small 
inhomogeneities still exist (usually more significant the farthest from the central bore of the 
magnet). In addition, certain tissues induce magnetic changes – depending on their magnetic 
susceptibility and add to these imperfections.  T2 decay tends to be 5-10 times faster than T1 
recovery for any given tissue type.   
 
1.3.2 MRI Signal Detection   
After excitation of the longitudinal magnetization, the resulting transverse magnetization 
will induce a sinusoidal voltage in an RF receive coil, which is the source of the MR signal. This 
signal needs to be significantly larger than any random or spurious fluctuations known as noise 
for good imaging. Signal-to-noise (SNR) levels in MRI imaging depend on the magnitude of the 
𝑀0⃗⃗ ⃗⃗  ⃗, which in clinical medicine – at body temperature, tends to be relatively small. Since M0 also 
depends on nuclear density, water protons in tissue are the best option for in-vivo imaging since 
they have the highest concentration (~88 mol/L). M0 also increases with the magnitude of the 
external magnetic field B0 (for e.g. from 1.5 to 3 T).  
For effective excitation and detection of the transverse magnetization, the RF coils are 
resonant antennas tuned to the Larmor frequency of a specific nucleus such as protons. Often a 
separate larger tuned transmit RF coil is used for uniform excitation of the protons and a smaller 
receive coil or array of coils are employed as close as possible to the region-of-interest for 
maximum signal reception since the receive signal decreases rapidly with distance.  
 
1.3.3 Pulse Sequences  
In order to acquire MR images, the excitation of the longitudinal magnetization and 
detection of the resulting transverse magnetization needs to be repeated multiple times. The set 




called a pulse sequence. Key pulse sequence parameters, which control the acquisition of MR 
images include:  
1) Time-to-repetition (TR) or “repetition time”, which governs how often the pulse 
sequence is repeated; 
2) Time-to-echo (TE) or “echo time”, which determines the time interval between signal 
measurements within a single TR; 
3) Flip angle (), which determines how much of the longitudinal magnetization is 
“tipped” into the transverse (xy) plane 
4) Number of excitations (NEX), which specifies the number of signal averages to 
improve SNR. 
These pulse sequence parameters are specified by the operator to obtain MR images with specific 
information and SNR.  
Since the transverse magnetization (Mt) decays quicker than the recovery of the 
longitudinal magnetization (Mz) after the application of the initial RF pulse, several techniques 
are used to reverse this decay and create an “echo” signal. Two common techniques are used in 
spin-echo and gradient-echo sequences. In spin-echo sequences, the dephasing of the spin is 
refocused by applying a 180˚ RF pulse (a certain time after the initial 90˚ pulse). This refocusing 
of the spins also reverses the effects of field inhomogeneities. On the other hand, in gradient-
echo sequences, the flip angle () is chosen to be less than 90˚, to ensure the longitudinal 
component (Mz) has an adequate magnitude, and a gradient magnetic pulse is utilized to refocus 
the dephasing (Fig. 1-7). Typically, with gradient-echo sequences, slice images are acquired one 














1.3.4 Proton Density, T1 and T2 Imaging  
Images in MRI can be T1-weighted, T2 (or T2
*)-weighted or proton density weighted, 
where the contrast between different tissues are enhanced based on their intrinsic T1, T2 and 
proton densities, respectively. Depending on the pulse sequence utilized, TE and TR (and even 
the flip angle) can be optimized to get any of the three types of images. Tables 1-3 and 1-4 
demonstrate the type of images obtained for standard spin-echo and gradient-echo sequences at 
different parameters.  
 
 Short TE Long TE 
Short TR T1- weighted mixed 
Long TR Proton-density weighted T2 weighted 
 





Figure 1-7: Gradient-echo sequence – showing the exciting RF pulses, the gradient (G(t)) 
magnetic field applied and the signal detected (initial and the echo formed by G(t)) over 




 Small Large 
Flip Angle (𝜽) Proton-density weighted T1-weighted 
TR T2
*-weighted T1-weighted 
TE Proton-density weighted T2
*-weighted 
 
Table 1-4: Type of images obtained with 1H MRI depending on the flip angle, TE and TR 
with gradient-echo sequences 
 
Note, that for spin-echo sequences T2-weighted images can be obtained since field 
inhomogeneities have been removed, while for gradient-echo sequences only T2
*-weighting can 
be obtained. In general, solid tissues with rigid lattices have increased spin-spin interactions and 
thus shorter T2, while in water these interactions are less, resulting in longer T2 values. As such, 





1.4 23Na Magnetic Resonance Imaging  
MRI requires a non-zero magnetic dipole moment to detect a nucleus. While current 
clinical MRI focuses on detecting hydrogen (due to its abundance in tissues and large 
gyromagnetic ratio), this technology can be adapted to detect other nuclei. In biological tissues, 
sodium yields the strongest MR signal after 1H. [69] The detection of sodium is possible since 
23Na nuclei possess a nuclear spin of 3/2. 23Na MRI has been utilized since the 1980s [70-76]; 
even so, this technology does have significant challenges and limitations.  
 
1.4.1 Technical Adaptation for 23Na MRI  
Since 23Na has different nuclear properties compared to 1H (Table 1-5), 23Na MRI 
requires specific technical adaptation – in terms of both RF hardware and pulse sequences. 
Custom RF coils are needed for the excitation and detection of the 23Na nuclei at their specific 
Larmour frequency. [77] These RF coils are highly optimized and can be paired with short echo 
times in pulse sequences to maximize possible SNR. Furthermore, these RF coils should not 
interfere with proton imaging, which are also needed for anatomical context. Lastly, since 23Na 
has specific excitation and relaxation properties, the pulse sequences used also need to be 
adapted (in terms of TR, TE and flip angle).   
 
 Spin Quantum Number Gyromagnetic Ratio (MHz/T) 
1H 1/2 42.6 
23Na 3/2 11.3 
 
Table 1-5: Difference between hydrogen and sodium nuclei in terms of their spin quantum 






1.4.2 Limitations and Challenges with 23Na MRI 
The main challenge with 23Na MRI is that relative to 1H, 23Na concentration in tissues is 
much lower. As shown in Table 1-2, 23Na concentration in the ICF and ECF is 143 and 12 
mmol/L, respectively. These values are approximately 1000 times smaller than the hydrogen 
concentration (~80mol/L), limiting the signal that can be acquired within a reasonable amount of 
time. In addition, since the signal for MRI scales as 𝛾3, the lower gyromagnetic ratio for 23Na 
also contributes to lower SNR.  
Furthermore, due to its 3/2 spin, 23Na exhibits a quadrupolar moment. This additional 
moment results in bi-exponential T2 relaxation with a short and a fast T2 component, which is 
dependent on the molecular environment. The short component generally contributes ~60% of 
the signal, while the long one corresponds to the remaining ~40% [78]. In order for both 
components to be detected, ultrashort TE (less than 0.5ms) and short T1 are required. [78] 
 
1.4.3 Quantifying Sodium Concentration with 23Na MRI  
In order to quantify absolute in-vivo sodium concentrations with MRI, the sensitivity 
profile of the RF system needs to be measured. This is typically undertaken in a separate 
experiment using an imaging phantom containing a uniform known concentration of sodium 
such as saline solution. Sodium MRI images are acquired for these phantoms, which are assessed 
for regional variation in signal. These relative signal maps are then used to normalize in-vivo 
sodium images. [79] In addition, for in-vivo 23Na MRI studies, three or four calibration vials with 
known sodium concentrations (spanning the expected range of sodium concentrations to be 
observed) are incorporated within the field of view of the receiving RF coil. Linear trend analysis 
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Chapter 2  
2 Non-Osmotic Sodium: What do we know? (A review) 
This chapter provides a review of the current knowledge of non-osmotic sodium: the 
rationale behind this hypothesis (Section 2.1), our current knowledge (Section 2.2), and its 
clinical significance (Section 2.3).  
 
2.1 Rationale behind Non-Osmotic Sodium Hypothesis  
Sodium is a key element that plays important biological roles in several physiological 
processes in the human body. While it is known that significant amounts of sodium are stored in 
the matrix of osseous tissue, mixed connective tissue and cartilage, [1-5] this stored sodium has 
been assumed to be relatively biologically quiescent and impervious to short term fluctuations in 
sodium intake and excretion. The biologically active sodium is believed to be the osmotically 
active one (O-Na), found primarily in the extracellular fluid compartment. This O-Na is thought 
to be strictly regulated primarily by the neurological osmostat and baroreceptors, and the 
kidneys. Furthermore, due to its aqueous state, it is assumed to be directly proportional to water 
balance. [6,7] For the purpose of this review, we refer to the sodium stored in tissues without a 
corresponding increase in water as non-osmotically active sodium (NO-Na). At steady state, 
humans are believed to have net neutral sodium and water balances [7]; thus, implying that 
sodium does not move freely between the osmotically active and non-osmotically active 
compartments. In fact, the NO-Na has largely been ignored in clinical medicine; for example, it 
is omitted from consideration in the treatment of patients with dysnatremias. [8-10] The 
corrective equations are based on water equilibrium and active osmolytes such as sodium and 
potassium. [8-10] 
Yet, follow up studies evaluating the accuracy of these equations and models have shown 
significant disparities between the expected and observed sodium corrections [10-15]. In a short 
term experiment, Engberink et al. [11] studied the effect of infusing 5mmol of sodium per L of 
total body water over 30min in 12 healthy individuals during the first four hours post infusion. 
They found that these models overestimated the change in plasma sodium - even when 




retrospectically assessed sodium balance in 38 critically ill patients during their first four days in 
an ICU setting, and found that while the plasma sodium did not change significantly, patients 
had a positive sodium balance of 1441±75 mmol (unaccounted by weight changes). A second 
observational study in the ICU setting found that the development of hypernatremia could not be 
explained by sodium and water balances. [14] 
Heer et al. [12]  performed a meticulously controlled, randomized study in 32 healthy 
males in a metabolic ward, where subjects were given diets with a set of different sodium 
quantities for at least 7 consecutive days. Sodium and water balances were calculated based on 
intake and excretion from the kidneys, gastrointestinal tract, sweat and insensible losses. Body 
fluid compartments were analyzed using inulin-dilution methods, mean corpuscular volume of 
erythrocytes and red cell mass. This group found that while higher sodium diets did result in 
larger plasma volumes, there was no significant change in the extracellular volume, intracellular 
volume or total body mass - despite positive sodium balances. 
Lastly, in a set of controlled simulated space-flight experiments lasting anywhere form 
105 to 205 days, [16-18] the sodium balance of healthy men was evaluated during longer periods 
of time. These experiments revealed that sodium accumulation was unrelated to changes in body 
weight (and thus extracellular compartment) and that in humans, regulation of sodium and water 
is not circadian. [16-18] 
A recent systematic meta-analysis of the current literature found that only 93% of the 
ingested sodium is accounted for in 24-hour urine collections; and when looking at studies in 
controlled environments, this amount dropped to 84%. [19] 
All these studies suggest an uncoupling of sodium and water homeostasis that could only 
be explained via a more fluid equilibrium between the osmotically active and non-osmotically 
active sodium storage compartments. This review focuses on our current knowledge of this non-
osmotically active sodium buffering system and its biological implications. 
 
2.2 Current Knowledge of Non-Osmotic Sodium   
A more fluid equilibrium between the O-Na and NO-Na stores has been hypothesized for 
more than 50 years. One of the first studies to notice an exchangeable reservoir of sodium in 
healthy individuals was completed in the 1960s. [20] In their study, Streeten et al. administered 




to 28 days – suggesting that the two sodium reservoirs equilibrate over time. [20] With the 
development of new technological advances, our current knowledge of this non-osmotic sodium 
buffering system has increased significantly. 
 
2.2.1 Measuring Techniques   
Several methodologies have been applied to quantify NO-Na stores. Initial studies [1-4] 
analyzed cadaveric human and animal bones by chemical and caloric removal of adherent 
tissues, water and fat. The left-over tissues were dissolved by HNO2 digestion in platinum 
crucibles and sodium content was determined with a lithium internal standard Barclay flame 
photometer. [21] Furthermore, several early studies utilized radio-active 22NaCl to analyze in-
vitro, [22] ex-vivo [3, 23] and in-vivo [20] sodium content of tissues. In these experiments, 23Na 
in the tissues was allowed to equilibrate with known concentrations of its radio-isotope 22Na, and 
radioactivity levels were measured to quantify sodium levels. In addition, in 1988 Warner et al. 
utilized electron probe analysis and analytical electron microscopy to detect ex-vivo sodium 
content in the layers of human skin. [24]    
More recently, in several ex-vivo studies, sodium content of tissues from animal or 
human sources was determined using ashing. [25-30] With this technique, tissues are initially 
desiccated and ashed, before sodium atomic levels could be measured with flame photometry 
[25,26] or atomic absorption spectrometry [27-30]. Alternatively, frozen tissue sections have 
been analyzed with inductively coupled plasma-optical emission spectrometry. [31] 
While the above methodologies are relatively accurate, they tend to be cumbersome 
(partly due to their invasive nature) and unsuited for repeat sampling attempts or in-vivo clinical 
settings. [26] Even the previous in-vivo assessments done by Streeten et al. [20] are limited due 
to radiation exposure. These limitations were eliminated with the advent of 23Na MRI. Since 
sodium is an ion with an odd atomic number – it is detectable by magnetic resonance detection 
and imaging. This relatively novel technology was first utilized in the 1980s and 1990s to image 
normal and ischemic canine and rabbit hearts. [32-34] Even so, Kopp at al. were the first to 
utilize 23Na MRI in assessing NO-Na content of tissues. [26] The accuracy of sodium 
quantification with 23Na MRI has been previously validated against ashing techniques in both 
animal and human studies. [26, 34, 35] In addition, Dyke et al. recently assessed its reliability in 




vivo, accurate, non-invasive measurements of sodium content in tissues of human beings, 
suitable for repetitive and dynamic quantification. 
 
2.2.2 Mechanism Non-Osmotic Sodium Storage   
Two main mechanisms for NO-Na storage in tissues have been proposed – with variable 
levels of supporting evidence: glycosaminoglycan (GAG)-bound and intracellularly-stored. 
 
2.2.2.1 Glycosaminoglycan-Bound Sodium  
One of the key components of the extracellular matrix are proteoglycans. These 
molecules consist of a core protein with one or more covalently-bonded long unbranched 
polymer of disaccharide units, or glycosaminoglycan.  GAGs can be sulfated, affecting their 
negative charge density. [37] This negatively charged GAGs are believed to recruit sodium 
atoms and render them non-osmotically active. [38,39] 
The association between increased tissue sodium and GAGs was first noticed by Ivanova 
et al. in the 1970s. [5] This Russian group demonstrated that in Wistar albino rats fed different 
sodium content, increased storage of sodium in the skin correlated with an increase in negatively 
charged sulfated GAGs. Similarly, in a series of experiments in Sprague-Dawley rats, higher skin 
NO-Na was associated with higher GAG content in skin, while sodium deprivation correlated 
with reduced sulfated GAGs and increased hyaluronan (non-sulfated GAG). [39,40] Direct 
correlations between tissue sodium and GAGs have also been demonstrated in cartilage tissue – 
where sodium concentrations can be as high as 250-300 mmol/L. [23,41-43] Lastly, Fischereder 
et al. [31] studied the tissue sodium content of skin, muscle and arteries in 27 dialysis patients 
and 21 healthy controls and found a significant association with GAG content. All these studies 
suggest that NO-Na storage in tissues may be dependent on the negatively-charged density of 
sulfated GAGs, an adaptable component of the extracellular matrix. 
 
2.2.2.2 Intracellularly Stored Sodium  
Bhave et al. speculated that excess sodium can also be stored intracellularly in highly 
cellular tissues like muscle. [44] In this hypothesis, sodium is exchanged for potassium and other 




changes in total body sodium often were accompanied by alterations in total body potassium, and 
once both these cations were accounted, total body water could be closely predicted. [45] 
Furthermore, in bovine cartilage, higher tissue sodium has been associated with increased density 
of the Na-K-ATPase pump (the main exchanger responsible for preserving gradients for sodium 
and potassium across membranes). [23] This suggests that cells may respond to the extracellular 
sodium levels by altering the density of this key exchanger. Furthermore, excess sodium could be 
stored in segregated intracellular compartments, while maintaining a relatively constant sodium 
concentration in the main cell cytoplasm. More studies are needed to delineate the exact storage 
mechanism of NO-Na. 
 
2.2.3 Current Knowledge  
Sodium concentration has been studied in several different tissues including skin, muscle, 
bone and cartilage. [26,39,44,46] Table 2-1 contains approximate ranges of sodium 
concentration in these tissues.  
 
 






Table 2-1: Approximate sodium concentration in different tissues, based on previous 
literature [26,39,44,46] 
 
 Several groups have studied whether this detected tissue sodium is truly osmotically 
inactive, by trying to assess concentrations in the interstitial fluid of skin tissue compared to 
plasma levels. Unfortunately, since the interstitial compartment consists of a GAG and collagen-
rich gel-like matrix - with pockets of entrapped free fluid, this fluid is not easily accessible for 




paraffin cavity technique and micropipettes to sample nanoliters of this fluid and found higher 
concentrations of sodium and potassium but lower concentrations of chloride, relative to plasma. 
[50-51] Higher cation concentrations, which cannot be explained by the Gibbs-Donnan effect, 
have also been found using the wick technique. [52] However, when Gilányi et al. [49] tried 
replicating these results, they found that the ion distribution in the interstitium and plasma 
corresponded to the Gibbs-Donnan equilibrium.  
Similar contradictory findings are seen in high sodium states. Nikpey et al. looked at the 
osmotic properties of interstitial fluid, lymph (derived from the interstitial fluid) and plasma in 
rats on a low salt diet (controls), compared to rats with increased sodium retention - induced by 
either high salt diet or deoxycorticosterone pellets. [30] These latter two groups had increased 
skin sodium accumulation (higher than water accumulation), and increased skin osmolality. 
Furthermore, using micropipettes, the authors found that, in all three groups, interstitial fluid, 
lymph and plasma were iso-osmolar. Yet, Wiig et al. [29] used micro-dialysis and energy-
dispersive x-ray electron microprobe analysis to find that sodium concentrations and osmolality 
were higher in the rat skin tissue and lymphatic fluid compared to plasma.  
There may be a number of reasons behind these discrepancies. First, the measuring 
techniques are prone to experimental error due to evaporation or intracellular fluid contamination 
– especially given the small sample sizes. [30,49,52] Second, the Gibbs-Donnan effect derived 
from the GAGs in the interstitial space is difficult to quantify, since the GAG concentration is 
dynamic. Third, multiple studies have demonstrated gradients in the osmolality and sodium 
content in the skin, [24,30] suggesting that depending on the exact area sampled, different 
concentrations can be obtained. More studies are needed to elucidate the exact nature of this 





2.3 Clinical Significance of Non-Osmotic Sodium 
2.3.1 Non-Osmotic Sodium and the Immune System 
The link between sodium and activation of the immune system has been known since the 
1990s, when hypertonic saline was noticed to enhance cellular immune function. [53-54] 
Recently, evidence has emerged that local sodium levels impact innate and adaptive immune cell 
function and vice versa. [55-56] 
Sodium has been shown to have a chemotaxis effect on macrophages, where higher 
sodium concentrations draw these cells into the tissues. [57] Furthermore, a series of in-vitro and 
in-vivo animal experiments have shown that the mononuclear phagocyte system (which includes 
macrophages, monocytes and dendritic cells) respond to tissue osmotic stress by increasing the 
transcription factor tonicity-responsive enhancer-binding protein (TONEBP, also known as 
NFAT5), and inducing on-site vascular endothelial growth factor C (VEGF-C). [29,58-59] This 
latter growth factor stimulates lymphatic hyperplasia, necessary for draining the interstitial fluid 
and electrolytes back into the intravascular compartment. Lymphatic hyperplasia has been 
observed with high-salt diets and sodium retention states. [29, 58-60] These lymphatic changes 
were prevented by blocking the pathway at the cellular and VEGF-C levels. Furthermore, 
depleting the mononuclear phagocytic system resulted in higher skin NO-Na levels in rats. [59] 
Thus, it is believed that by increasing lymphatic drainage, the mononuclear phagocyte system 
can influence the NO-Na levels in the tissues.   
On the other hand, sodium has also been shown to have direct and indirect effects on the 
immune system. In-vitro studies have shown than high sodium cultures induce pro-inflammatory 
changes in T-helper and T-regulatory cells, macrophages, and dendritic cells. Furthermore, high 
salt diets have been associated with increased inflammatory cytokines, and several auto-immune 
conditions and infections in both animal and human studies.  Lastly, sodium also affects the 
intestinal microbiome, which plays a significant role in immune activation. These findings have 
been previously summarized in the literature. [55-56,61-62] For the purpose of this review, we 
will focus on the effect of NO-Na on the immune system from a clinical perspective.   
Multiple studies have demonstrated increased levels of NO-Na – as measured by sodium 
MRI technology, in infectious, inflammatory and ischemic conditions. Jantsch et al. studied 




skin had higher NO-Na levels, and that antibiotic treatment decreased these levels toward those 
of un-infected controls. [63] Furthermore, they looked at in-vitro macrophage elimination of 
intracellular Escherichia coli and Leishmania major infections in high and low sodium chloride 
media and discovered that high sodium boosted clearance of these infections through NFAT5 (or 
TONEBP) activation and increased nitric oxide production. Lastly, they infected mice (fed high 
and low salt diet) with Leishmania major in their footpads and found that higher tissue sodium 
levels were associated with faster healing. They concluded that sodium accumulation in the skin 
microenvironment may strengthen host defenses against infection.  
In addition, NO-Na has been associated with ischemic conditions in the heart and the 
brain. Animal studies with induced coronary ischemia and reperfusion demonstrated increased 
NO-Na in the affected myocardium, corresponding to non-viable tissue, but normal values in the 
hibernating tissue (penumbra). [33-35,64] Similar findings were seen in humans studied with 
23Na MRI post myocardial infarction. [65-66] Sodium levels reached a peak 4-days post infarct, 
then trended down and stabilized by 90-days post. [65] After 90 days, the NO-Na level in the 
damaged myocardium did not correlate with infarct age, or functional or morphological indices. 
[66] Analogously, in the brain, NO-Na levels in stroke areas are elevated; yet, sodium signal in 
the penumbra (tissue amenable to salvage with reperfusion therapy) is preserved. [48] These 
findings suggest that ischemia may result in altered sodium content – potentially through 
inflammatory effects or altered trans-cellular sodium gradients. Furthermore, in ovariectomized 
rats, high salt diet and higher tissue sodium was associated with increased ischemic neurological 
damage. [67]  
Lastly, two main inflammatory conditions have been studied with regards to their 
association with NO-Na: multiple sclerosis and scleroderma. Multiple sclerosis has been studied 
by several groups, who have demonstrated increased sodium levels, not only in the demyelinated 
lesions of the brain, but also in the total gray and white matter. [68-73] In addition, higher NO-
Na levels were associated with increased disease severity and clinical disability. The increased 
NO-Na in this disease may result from a combination of neuro-axonal metabolic dysfunction 
(resulting in increased intracellular sodium) and interstitial inflammation. [72] Similarly, 
systemic scleroderma lesions in the skin were also associated with increased NO-Na levels, and 




NO-Na and the immune system appear to be significantly interdependent based on 
current evidence, and further investigations will be crucial in elucidating this relationship. Yet, 
clinically, 23Na MRI technology and the relative changes in NO-Na levels already show 
significant promise as diagnostic and prognostic tools in inflammatory conditions. 
 
2.3.2 Non-Osmotic Sodium, Hypertension and the Endocrine System 
 The link between sodium and hypertension is long-recognized, and sodium restriction is 
a common recommendation for hypertensive patients. The advent of a non-osmotic buffering 
system for sodium opened up a new area of research in this field. In both animal and human 
studies, hypertension (particularly refractory hypertension) has been associated with increased 
skin NO-Na levels. [26,28,75] The relationship between NO-Na and blood pressure has been 
extensively reviewed in the literature. [38,76-77] We will review some of the key players 
affecting this relationship.  
The first key player is the immune system. As discussed above, the immune system plays 
an important role in regulating NO-Na by the activation of the mononuclear phagocytic system, 
production of VEGF-C and lymphatic hyperplasia. Blocking this inflammatory response results 
in salt-sensitive hypertension in mice and rats. [29,58-59] This suggests that the immune system 
plays an important role in blood pressure regulation by altering the non-osmotic buffering system 
of sodium. [26] 
The second key player is the endocrine system. In the simulated space-flight experiments 
looking at sodium balance in humans, 24-hour urine sodium excretion exhibited a circaseptan (7 
days) and circalunar (approximately monthly) rhythmic pattern, which appeared to be under the 
control of aldosterone, cortisol and cortisone levels. [16,78] Furthermore, skin sodium levels are 
particularly higher in patients with hyperaldosteronism, and improve with surgical or 
spironolactone treatments. [26] Aldosterone may also influence the immune response to sodium. 
Dendritic cells have been found to express epithelial sodium channel (ENaC), a membrane 
transporter typically under aldosterone control. [79] These findings would suggest that 
aldosterone and corticosteroids impact NO-Na storage; whether directly or indirectly through 
renal excretion remains to be studied.  
Two other hormonal axes that have been partially studied with regards to their relation to 




the amount of sodium stored in skin and muscle. [26,75,80-81] Furthermore, ovariectomy 
resulted in decreased sodium storing capacity in the tissues of female rats, and greater fluid 
retention. [28] In addition, insulin resistance has been shown to be associated with higher mean 
arterial blood pressure in diabetics and exogenous insulin decreases the urine fractional excretion 
of sodium.[82] In two studies of hemodialysis patients, increased muscle sodium levels was 
associated with insulin resistance, while diabetes was associated with higher NO-Na deposition 
in both skin and muscle.[83-84] These findings suggest roles for insulin, estrogen, progesterone 
and testosterone that need to be further elucidated.  
Thirdly, the existence of osmolyte gradients in the skin has given rise to a theory of extra-
renal countercurrent system in the skin that has direct effects on blood pressure. [38,77,85] The 
skin has been shown to have osmolality, urea and sodium gradients. [24,30] The similarity of 
these gradients to those found in the kidney, make them particularly interesting as a novel 
mechanism of hemodynamic control. Thus, blood pressure and NO-Na likely have some direct 
correlation based on these osmolyte gradients in the skin, and indirect ones through multiple 
hormonal axis and the immune system.    
 
2.3.3 Non-Osmotic Sodium and Malignancy  
Increased tissue sodium has been detected in neoplastic lesions (compared to normal 
tissue) in the breast, prostate and brain. [86-91] In addition, pathologically more aggressive 
lesions had the highest sodium concentration in prostate and brain, indicating that this index may 
be of use clinically for prognostication. [88,91] In malignant lesions, the increased sodium signal 
detected with 23Na MRI has been attributed to a breakdown of local cellular energy-based 
sodium transporters (sodium-proton antiport and Na-K-ATPase) and sustained cell 
depolarization – resulting in higher intracellular sodium levels, and increased extracellular 
sodium from disruption of the necrotic tumor cells. [86,88,90-91] Unfortunately, current 
knowledge is still quite limited.  
 
2.3.4 Non-Osmotic Sodium and Degenerative Diseases  
NO-Na has been associated with several degenerative conditions and structural changes 




In skeletal muscle, 23Na MRI was utilized to assess sodium levels in aerobic and 
anaerobic exercise. [92] An increase in NO-Na was observed with anaerobic exercise only. The 
authors speculated that this increase could be from higher intracellular sodium concentration due 
to depletion of the Na-K-ATPase. The lack of response with aerobic exercise remains a puzzle. 
Yet, increased NO-Na attributed to intracellular shifts has also been recorded in other 
channelopathies, namely during cold and exercise-induced weakness in severe hyperkalemic 
periodic paralysis. [93] In addition, two patients with myotonic dystrophy also had increased 
sodium signal in their skeletal muscles, compared to healthy controls. [94]  
In the brain, in a study of 10 patients with drug-resistant epilepsy and 27 healthy controls, 
increased sodium levels were found in the epileptogenic zones (compared to irritated or non-
involved regions) in the inter-ictal state. [47] Since sodium ions are key for the maintenance of 
the transmembrane gradient crucial to normal neuronal action potential, this change (in the 
absence of seizure activity) was attributed to ongoing modification of the processes governing 
transmembrane sodium concentrations. In fact, alterations in voltage-gated sodium channels have 
been shown to be triggers in epileptic neuronal tissue. [95-97] Furthermore, increased tissue 
sodium has been seen in patients with Alzheimer’s and Huntington’s degenerative disorders. [98-
99]  
Unfortunately, the main limitation of these studies is their relatively small sample sizes 
(usually less than 13 patients per group). Even so, current findings suggest that NO-Na may 
serve as a diagnostic tool to identify regions of interest with structural or functional anomalies in 
tissues. 
 
2.3.5 Non-Osmotic Sodium and Sodium Surplus States: Heart and 
Kidney 
NO-Na has also been studied in conditions traditionally associated with increased-sodium 
retention: specifically heart failure and kidney disease. Hammon et al. (2015) studied 9 patients 
with acute exacerbation of congestive heart failure (CHF), before and after diuretic therapy, 
compared to healthy control. [100] They found that patients had higher levels of sodium in both 
skin and muscle, and that diuretic therapy significantly reduced sodium content in both these 
tissues. Furthermore, water content was not reduced with treatment in muscle, but did show a 




significant NO-Na in the muscle and potentially a combination of osmotic and non-osmotic 
sodium storage in the skin.  
NO-Na has also been studied in renal conditions – where the ability of the kidneys to 
excrete sodium may be compromised. Hammon et al. (2017) studied patients with acute kidney 
injury. [101] They found that these patients did have higher NO-Na in both skin and muscle, 
compared to healthy control. Yet, hemodialysis treatment did not significantly change these 
levels, despite lowering blood pressure and weight. Dahlman et al. studied 33 patients on chronic 
hemodialysis, and discovered that only patients older than 60years had increased skin and muscle 
sodium compared to healthy controls. [102] Higher sodium levels were associated with 
decreased VEGF-C. Furthermore, sodium stores in these tissues was successfully mobilized with 
hemodialysis treatments.  
Olde Engberink et al. have proposed that the endothelial surface layer, which tends to be 
quite rich in glycosaminoglycans, may play an important role in adjusting NO-Na. [103] This 
endothelial layer is itself composed of a combination of GAGs – a microenvironment highly 
regulated by endothelial cells. [104] As such, this group proposed that this layer may serve as the 
first layer in regulating the passage of sodium between the osmotic and non-osmotic 
compartments. Furthermore, this endothelial layer is often damaged in renal disorders, [105,106] 
which may explain the altered sodium handling by the kidneys in diseased conditions. Lastly, 
NO-Na accumulation in CKD has been associated with end-organ damage; specifically, 
increased skin NO-Na in mild to moderate CKD patients was associated with left ventricular 
mass. [107] 
 Thus, the relationship between the kidney and sodium is likely more complicated than 
previously appreciated. Sodium handling by the non-osmotic compartment and the endothelial 
layer could result in renal injury, and diminished renal function may increase NO-Na – though 
likely affected by other factors, like age. More studies are needed to shed more light on these 






The discovery of a non-osmotic sodium buffering mechanism has resulted in a better 
understanding of sodium hemostasis. Previously, sodium was believed to have a role restricted to 
that of an effective osmolyte necessary for hemodynamic stability and for maintaining the 
transmembrane electric potential. With the above studies, the role of non-osmotic sodium as a 
key player in creating tissue micro-environments and affecting multiple signaling pathways and 
biological process is becoming more obvious. More studies are needed to elucidate this 
compartment further (e.g. in terms of its location – intracellular or extracellular) and reveal its 
full potential. Furthermore, the use of 23Na MRI opens a door of possibilities to study this non-
osmotic sodium compartment and use it in clinical medicine for diagnostic, and prognostic 
purposes. Lastly, a better understanding of sodium’s multitude of roles and effects, can even lead 
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Chapter 3  
3 Non-Osmotic Sodium in CKD 
This chapter contains a condensed introduction (background and the study objective and 





Sodium is a key element that plays important biological roles in several physiological 
processes. For years, the paradigm of 23Na homeostasis in humans relied on the assumption that 
the majority of the biologically active sodium is stored osmotically solvent in the extra-cellular 
volume, and that body sodium content is regulated primarily by the kidneys. 23Na storage 
independent of water retention was often neglected. Even so, multiple short and long-term 
studies in humans have shown that 23Na mass balance cannot be maintained without the 
existence of a non-osmotic 23Na compartment. [1-4] This compartment has further been studied 
and quantified, [5-7] especially with the advent of 23Na MRI technology. [8-16] Current 
evidence suggests that this non-osmotic 23Na is bound to glycosamino-glycans (GAGs) in the 
extracellular matrix of tissues. [17-21] Sodium deposition has been linked to multiple 
physiological and pathological processes including: exercise, hypertension and 
hyperaldosteronism, congestive heart failure, malignancy, inflammation, and ischemia. [6-7,9-
11,13,21-23] 
Sodium homeostasis is fundamentally altered in patients with kidney disease – due to the 
lack of renal sodium excretion. [30-33] As such, patients with chronic kidney disease may have a 
higher utilization of this non-osmotic 23Na buffering system. Previous studies have demonstrated 
increased skin and muscle 23Na in patients undergoing acute hemodialysis treatment and those 
older than 60 years on chronic HD – relative to healthy controls. [10,12] Even so, in a cohort of 
patients with stage 1-3 of kidney disease, Schneider et al. did not find a correlation between 
estimated glomerular filtration rate (eGFR) and skin 23Na. [14] The effect of the severity of 






3.1.2 Study Hypothesis and Objective  
The objectives of this thesis are: 
1) To use 23Na MRI technology to examine the sodium deposition in skin, muscle and 
skeleton tissues of two groups of CKD patients: 1) CKD stage 4-5 (not dialysis) 
patients, and 2) dialysis patients – sub categorized into PD and in-center HD, and 
compare this deposition with controls with normal kidney function.  
Hypothesis: Since the kidney plays a key role in regulating sodium content in the body, and since 
patients with CKD have altered sodium excretion, we hypothesized that CKD patients would 
have higher levels of non-osmotic sodium in their tissues. In addition, we hypothesized that the 
degree of non-osmotic sodium would be dependent on the stage of kidney function, i.e. patients 
with end-stage kidney function on renal replacement therapy would have more sodium in their 
tissues than patients with stage 4-5 CKD (not on dialysis). Also, since peritoneal dialysis patients 
tend to have higher residual renal function, we speculated that they would have lower sodium 
levels than patients on in-center hemodialysis.  
 
2) To explore associations between sodium deposition in these tissues with baseline 
characteristics and biochemical markers, to explore specific correlations. 
Hypothesis: Given the many associations between non-osmotic sodium and physiological 
functions (discussed in Chapter 2), we suspected that sodium accumulation may be associated 








3.2.1 Study Design 
This is a pilot cross-sectional cohort study of patients with different levels of kidney 
disease: CKD 4-5 not on dialysis (CKD group), and dialysis - peritoneal dialysis (PD) and 
hemodialysis (HD); compared to controls with normal kidney function (Control group). During 
the study sessions, we obtained baseline characteristics (including age, sex, past medical history, 
medications, and renal history), blood work for biochemical analysis, and MRI study of the right 
lower leg, for each participant.  
This study was approved by the University of Western Ontario Health Sciences Research 
Ethics Board and was conducted in compliance with the approved protocol, Good Clinical 
Practice Guidelines and all applicable regulatory requirements. 
 
3.2.2 Subjects 
Controls from London, Ontario, and CKD and dialysis (both PD and HD) patients from 
London Health Sciences Centre – Regional Renal Program participated in the study. All 
participants had to be 18 years or older and provided written informed consent prior to the study. 
Subjects were considered controls if they lacked any history of kidney disease, heart failure, liver 
cirrhosis or peripheral edema. This group was recruited through posters advertising the study in 
the London community (hospitals and churches). CKD patients had to have CKD Stage 4-5 
disease (as defined by Kidney Disease: Improving Global Outcomes 2012 Guideline [34]) and 
no indications to start dialysis. Dialysis patients included PD and in-center thrice-weekly HD 
patients who had been established on their respective dialysis modality for at least 3 months. 
Subjects were excluded if they were pregnant, breast-feeding, intending pregnancy or unable to 
provide consent, or if they had any contraindication to MRI studies. 
 
3.2.3 Biochemical Measurements 
Plasma, serum and blood specimens from each subject were collected, processed and 
analyzed by a central laboratory (London Health Sciences Centre, London, Canada) for routine 
clinical chemistry of a core set of parameters. eGFR values were estimated using the Chronic 





3.2.4 Sodium MRI Quantification of Tissue Sodium  
Tissue 23Na concentration in the lower leg tissues was assessed non-invasively using MRI 
technology, similarly to previously described methods. [8-9] This technology has been 
previously validated against sodium quantification with chemical analysis by ashing, [8] and has 
been found to be reliable. [36] A multinuclear-capable 3.0-T MRI (Discovery MR750, General 
Electric Healthcare, Milwaukee, WI) was used to acquire proton and sodium images. Subjects 
were positioned supine in the magnet bore with the right lower leg (10-15 cm below the knee) 
centered in a custom-made 12-rung 18-cm-diameter 23Na birdcage radiofrequency (RF) coil (Fig. 
3-1). Calibration vials with 10, 20 and 40 mmol/L of saline were placed in the RF coil, over the 
subjects’ shins. Axial proton T1-weighted images with a fast-low-angle-shot (FLASH) sequence 
were acquired to delineate the anatomy of the lower leg. A single-slice 23Na MR image was 
obtained with a density-adapted three-dimensional radial projection reconstruction pulse 
sequence optimized for sodium acquisition, [37] with the following parameters: slice-selective 
RF pulse with a 90° flip angle, TR/TE: 100/1.5ms, total acquisition time: 30min, number of 










Maps of tissue 23Na concentration were generated with Matlab (Mathworks, Natick, 
USA, R2018a), using the calibration vials relating signal intensity to 23Na concentration using 
linear trend analysis. 23Na concentration maps were superimposed with the proton anatomical 
images to delineate the regions of interest. Four regions of interest (ROIs) were drawn, using 
OsiriX Lite (Version 9.5.2) software, highlighting different tissues: 1) pre-tibial skin, 2) posterior 
leg skin, 3) soleus muscle, and 4) tibia (including bone marrow) (Fig. 3-2). Two skin regions 
were included - based on reproducibility, because 23Na distribution in this tissue was relatively 
inhomogeneous. This inhomogeneity in sodium content could make one of these areas more 
clinically relevant. In addition, the bone marrow was included in the tibia ROI because the 
sodium signal from the bone marrow and the osseous tissues were comparable in our preliminary 










Figure 3-2: Sample overlap image with sodium MRI image (gray scale) and proton image 








3.2.5 Data Analysis  
Statistical analysis was performed using SPSS Statistics, Version 23 (IBM, Chicago). 
Data were analyzed using descriptive statistics (means with standard deviation (SD) or 95% 
confidence intervals (CI) for continuous variables; percentages for categorical variables). 
Kruskal-Wallis, Anova and Fisher’s exact tests were used to compare groups across baseline 
characteristics. Mann-Whitney and t-tests were applied to unpaired observations. Correlations 
were assessed by calculating Pearson (r) and Spearman (rho) correlation coefficients. We then 
performed some exploratory multiple regression analysis to examine the parameters that 
independently influence tissue 23Na concentration. The basic regression models were generated 
using age, sex, and the parameter with the strongest correlation (r or rho) from each of the main 
areas: inflammation, bone mineral disease, and blood pressure. Other variables with strong 
correlation (p<0.01) were then added to the basic model sequentially. F-statics were used to 
remove factors who did not significantly contribute to the model. The models were compared 
using corrected R2 coefficient. Due to the exploratory nature of these models, interactions 
between the factors were not assessed. Furthermore, these parameters were not adjusted for renal 
function. Missing data were managed by removing that subject from that particular analysis. 







In total, 10 Control, 12 CKD, and 23 dialysis (10 PD and 13 HD) subjects participated in 
the study (Fig. 3-3). 56% of all participants were male and 84% were Caucasian. Table 2-1 
highlights the baseline characteristics of these groups. CKD and dialysis subjects were older and 
had higher weights and BMIs. As expected, they also had higher rates of comorbidities 
including: hypertension, atherosclerosis, and congestive heart failure. Correspondingly, subjects 
with kidney disease had significantly higher use of anti-hypertensive medication and other renal-
specific medications (erythropoietin-stimulating agents and phosphate binders).  The main 
etiologies of renal disease included hypertension, diabetes mellitus, reno-vascular conditions, 
glomerulonephritis and other (some subjects had multiple etiologies). The three groups also 
varied across multiple serum biomarkers – most of which are explained by the presence of 
kidney disease. Notably, serum sodium was different among the groups, with means of 
141mmol/L, 139.9mmol/L and 138.3mmol/L in the Control, CKD and dialysis groups (PD and 
HD) respectively (p-value 0.01).  
 
Figure 3-3: Study Population: including recruited participants who were withdrawn, and 




10 Controls 12 CKD Patients
23 Dialysis Patients:
- 10 Peritoneal Dialysis
- 13 Hemodialysis
Withdrawn:
2 HD patients - withdrew consent




When comparing the PD and HD subgroups (Table 3-1), PD subjects had higher residual 
renal function (means of 1175ml vs 220ml, p-value 0.003), and higher use of diuretic therapy 
(100% vs 23.1%, p-value <0.001). These two subgroups also varied in a number of serum 
biomarkers, consistent with the different clearance-characteristics of these dialysis modalities. 
PD subjects had statistically significant higher creatinine and lower albumin concentrations. 
Lastly, HD participants had higher hemoglobin levels compared to PD ones, 120.3 g/L vs 104.0 
g/L respectively (p-value 0.01). High sensitivity C-reactive protein (CRP) was not statistically 






Table 3-1: Baseline characteristics for the three study groups, and for the two subgroups (HD and PD). 
 
Parameter  Control (n=10) CKD (n=12) Dialysis (n=23) p-value HD (n=13) PD (n=10) p-value* 
Age, year, mean (SD) 53.3 (19.4) 66.3 (6.7) 61.6 (9.4) 0.04 62.5 (9.1) 60.3 (10.2) 0.59 
Sex, men/women 4/6 8/4 14/9 0.52 9/4 5/5 0.42 
Race, Caucasian/other 8/2 12/0 18/5 0.228 8/5 10/0 0.046 
Height, cm, mean (SD) 167.3 (7.0) 166.4 (9.8) 170.8 (7.7) 0.24 171.2 (7.5) 170.3 (8.4) 0.78 
Weight, kg, mean (SD) 70.5 (8.2) 88.5 (18.6) 83.5 (18.7) 0.047 83.9 (22.6) 83.1 (13.0) 0.92 
BMI, kg/m2, mean (SD) 25.2 (2.7) 31.7 (4.5) 28.6 (6.1) 0.02 28.4 (7.0) 28.8 (5.0) 0.89 
        
Comorbidities  
       
Hypertension, % 10.0 91.7 87.0 <0.001 100.0 70.0 0.07 
Atherosclerosis, % 0 50.0 43.5 0.02 46.2 40.0 1.00 
Coronary artery disease, % 0 16.7 21.7 0.36 30.8 10.0 0.34 
Cerebrovascular disease, % 0 16.7 13.0 0.58 15.4 10.0 1.00 




Congestive heart failure, % 0 0 26.1 0.04 30.8 20.0 0.66 
Diabetes Mellitus, % 10.0 58.3 43.5 0.053 46.2 40.0 1.00 
COPD, % 0 0 17.4 0.16 23.1 10.0 0.60 
        
Etiology of Kidney Disease  
       
Hypertensive nephropathy, % - 41.7 44.5 0.04 38.5 50.0 0.69 
Diabetic nephropathy, % - 33.3 39.1 0.06 38.5 40.0 1.00 
Glomerulonephritis, % - 16.7 8.7 0.54 15.4 0 0.49 
Vascular nephropathy - 25.0 39.1 0.053 46.2 30.0 0.67 
Other  - 41.7 30.4 0.06 30.8 30.0 1.00 
        
Dialysis vintage, months, mean (SD) - - 37.1 (34.3) - 47.1 (41.7) 24.2 (14.8) 0.09 
Residual renal function, ml, mean (SD) - - 635 (721) - 220 (326) 1175 (746) 0.003 
        
Medications 




Anti-hypertensives, % 10.0 91.7 78.3 <0.001 84.6 70.0 0.62 
ACEI/ARB, % 10.0 58.3 30.4 0.053 30.8 30.0 1.00 
Diuretic, % 10.0 58.3 56.5 0.03 23.1 100.0 <0.001 
Beta blocker, % 0 66.7 65.2 0.001 76.9 50.0 0.22 
Calcium channel blocker, % 0 41.7 52.2 0.01 46.2 60.0 0.68 
ESA, % 0 25.0 60.9 0.001 69.2 50.0 0.42 
Phosphate binders, % 0 33.3 87.0 <0.001 84.6 90.0 1.00 
Calcium Binders, % 0 33.3 82.6 <0.001 76.9 90.0 0.60 
Aspirin, % 10.0 66.7 39.1 0.003 38.5 40.0 1.00 
        
Serum Biomarkers 
       
Sodium, mmol/L, mean (SD) 141 (2.2) 139.9 (1.8) 138.3 (2.8) 0.01 138.4 (2.6) 138.1 (3.2) 0.81 
eGFR, ml/min/1.73m2, mean (SD) 88.1 (16.1) 23.1 (11.8) - <0.001 - - - 
Creatinine, µm/L, mean (SD) 77.0 (12.2) 257.3 (83.5) 630.7 (242.3) <0.001 557.7 (215.3) 718.3 (254.3) 0.13 
Albumin, g/L, mean (SD) 43.7 (2.5) 43.3 (2.4) 39.0 (4.4) 0.002 41.2 (3.6) 36.7 (4.0) 0.02 




CRP, mg/L, mean (SD) 2.2 (2.6) 2.9 (2.4) 13.7 (16.9) <0.001 15.8 (22.1) 10.6 (7.3) 0.46 
PTH, pmol/L, mean (SD) 4.5 (1.2) 18.8 (16.9) 40.7 (40.3) 0.001 44.8 (42.9) 35.9 (38.7) 0.62 
hsTroponin T, ng/L, mean (SD)  5.5 (3.2) 27.8 (16.9) 130.1 (157.4) <0.001 165.2 (196.7) 88.0 (83.3) 0.24 
p-value* - comparing HD and PD; p-values calculated with Fisher’s exact test.  
ACEI – Angiotensin converting enzyme inhibitor, ARB – Angiotensin II receptor blocker, BMI – Body mass index, COPD – Chronic 
obstructive pulmonary disease, CRP – high sensitivity C-Reactive protein, eGFR- Estimated glomerular filtration rate – using CKD-
EPI equation, [35] ESA – Erythropoietin stimulating agent, hsTroponin T – High sensitivity troponin T, PTH – Parathyroid hormone, 







Figure 3-4: Examples of sodium concentration maps for the different study groups: 
control, CKD, HD and PD. (Colour map on the side indicates the sodium concentration in 
mmol/L) 
 
Four representative examples of tissue 23Na concentration maps are shown in Fig. 3-4. The 
23Na concentration in the study groups for the four regions of interest is shown in Fig. 3-5. 23Na 
levels were statistically higher in dialysis subjects compared to healthy controls (p<0.05) across 
all tissues. No statistically significant difference was found between 23Na levels in dialysis and 
CKD subjects. CKD participants had statistically significant higher 23Na levels in their tibia and 
posterior leg skin compared to controls. Furthermore, when the dialysis group was split into HD 
and PD subgroups, no difference was found between PD, HD and CKD. Yet, all three had higher 
23Na in the tibia and posterior leg skin compared to the control group. Only PD subjects had 











Figure 3-5: Tissue Sodium Concentration in the study groups. A – results for the main 





Correlations between 23Na levels in the four tissues, and different subject parameters 
were also explored (Table 3-2). Multiple statistically significant correlations were discovered 
between 23Na levels and baseline characteristics, medications, and renal, inflammatory, mineral 
bone disease and end-organ markers. Some correlations were persistent across the four tissues 
studied (e.g. correlations with parathyroid hormone, high sensitivity troponin T and 
inflammatory markers).  Conversely, some parameters were associated with 23Na levels only in 
specific tissues (e.g. increased age was associated with higher 23Na in soleus and posterior leg 
skin only).  Serum sodium levels did not correlate with 23Na concentrations of any of the tissues 
studied.  
Multi-variable regression linear models are shown in Table 2-3. Tibia and soleus 23Na 
levels were explained relatively well by the third models (R2 0.713 and 0.603, respectively). The 
models for pretibial and posterior leg skin were weaker (models 2 had R2 0.274 and 0.456, 
respectively). These models were not improved by the addition of other parameters (including 
age (when not already included), sex, hypertension, and eGFR; data not shown). Each tissue had 

















Corr. Coeff. – Correlation coefficient, ALP – Alkaline phosphatase, CHF – Congestive heart failure, COPD – Chronic obstructive 
pulmonary disease, CRP – high sensitivity C-Reactive protein, eGFR- Estimated glomerular filtration rate – using CKD-EPI equation, 




Table 3-3: Linear regression models for explanation of 23Na in the different tissues studied. 
 
Tibia Model 1 Model 2 Model 3 
 
R2 0.474 R2 0.670 R2 0.713 
Parameter Beta Coeff. p-value Beta Coeff. p-value Beta Coeff. p-value 
Hemoglobin -0.689 <0.001 -0.504 <0.001 -0.367 0.003 
PTH 
  
0.479 <0.001 0.479 <0.001 
Albumin 
    
-0.249 0.030 
       
Soleus Model 1 Model 2 Model 3 
 
R2 0.450 R2 0.528 R2 0.603 
Parameter Beta Coeff. p-value Beta Coeff. p-value Beta Coeff. p-value 
Albumin -0.677 <0.001 -0.620 <0.001 -0.547 <0.001 
PTH 
  
0.270 0.021 0.291 0.008 
Age 
    
0.283 0.011 
       
Post-Leg 
Skin Model 1 Model 2 
 
 
R2 0.304 R2 0.456 
 
Parameter Beta Coeff. p-value Beta Coeff. p-value 
  






       
Pretibial Skin Model 1 Model 2 
  
 
R2 0.178 R2 0.274 
 
Parameter Beta Coeff. p-value Beta Coeff. p-value 
 






Beta coeff. – standardized coefficient 
PTH – Parathyroid hormone, eGFR- Estimated glomerular filtration rate – using CKD-EPI 





3.4 Discussion and Conclusions 
In our study we found that there was a statistically significant increase in 23Na 
accumulated in the tissues of dialysis patients compared to controls with normal kidney function. 
Evidence of sodium accumulation was observed even in CKD patients (even if not always 
statistically significant). No statistically significant difference was found in the 23Na levels 
among CKD, PD and HD participants. In addition, we found significant associations between 
23Na levels and markers for mineral bone disease and inflammation. Even so, the major 
contributing parameters were tissue specific. 
 
3.4.1 Age and Sex, and Sodium 
In healthy controls, sex and age have been correlated to skin and muscle 23Na levels. 
[9,38] Age has also been associated with higher 3Na deposits in the skin of patients with mild 
CKD. [14] The effect of age on hemodialysis patients has been inconsistent. Dahlmann et al. 
[10] showed increased skin 3Na in older subjects, while Fischereder et al. [20] did not observe an 
age-related effect. As demonstrated in Tables 3-2 and 3-3, age did correlate with 23Na deposition 
in the posterior-leg skin, soleus and tibia, however this effect lost its statistical significance in the 
multivariable regression models. An opposite phenomenon was observed between age and 
pretibial skin. These inconsistencies suggest a need for larger in-depth studies.  
There were no observed changes in 23Na deposition in the tissues based on sex. Similarly, 
Fischereder et al. did not detect a difference in 23Na deposition based on sex, in hemodialysis 
patients. [20] Even so, Schneider et al. showed that in patients with mild CKD, male sex was 
associated with significantly higher levels of skin 23Na. [14] We postulate that the sex-effect may 
be overshadowed by the altered pathophysiology in severe CKD. Since the majority of our 
participants had CKD - Stages 4-5D, we speculate that in this population, CKD- related factors 
may supersede the effect of sex on non-osmotic 23Na deposition in the tissues. 
 
3.4.2 CKD and Sodium  
Our study found an increase in 23Na accumulation in dialysis and CKD patients relative 
to controls in all tissue types, not just skin and muscle. This is the first study that has reported on 
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measurement of sodium levels in osseous tissue with23Na MRI, and found increased sodium 
deposition even in this compartment.    
While the groups were statistically different with regards to their measured serum sodium 
(Table 3-2), controls had the lowest tissue 23Na concentrations despite having the highest serum 
sodium levels. This confirms that tissue and serum sodium are not correlated.  Our skin and 
muscle 23Na concentrations were similar in range to previously reported values (range of 10-50 
mmol/L).[10,12,14]  
Hammon et al. found similarly higher sodium accumulation in the skin and muscle of 
new-hemodialysis-start patients compared to healthy controls. [12] However, two other groups 
did not show a difference between 23Na deposition in the skin and muscle of HD patients versus 
controls. [10.20] This discrepancy may be due to the different populations studied, with previous 
studies focusing solely on HD patients, as opposed to both HD and PD patients. Our study is the 
first one to include PD and CKD stage 4-5 patients. Yet, even when we compare the HD 
subgroup and controls, 23Na in the soleus muscle and posterior leg skin is still significantly 
higher. All these studies are relatively small, involving less than 30 HD patients. Larger studies 
are needed to resolve the different findings.  
Of note, while eGFR and creatinine had statistically significant correlations with tissue 
23Na (Table 3-2), when these parameters were added to the regression models, the b-coefficients 
were not statistically significant (data not shown). Furthermore, both of these parameters are 
difficult to interpret in the setting of dialysis, since both PD and HD will affect these values. As 
such, these data should be interpreted carefully. It is difficult to determine from our data if 
kidney function has a direct or indirect (by altering inflammation and other parameters) effect on 
sodium levels, or if these results are due to confounding factors.  
 
3.4.3 Inflammation and Sodium  
Our study did demonstrate significant correlations between the measured inflammatory 
markers (CRP, albumin and hemoglobin) and tissue 23Na deposition – and all but two of these 
associations were statistically significant (Table 3-2). The correlations of inflammatory markers 
with muscle and bone and posterior leg skin 23Na appear to be more robust – persisting even in 
the linear regression models. This finding is consistent with pre-existing literature, where non-
osmotic sodium is closely related to inflammatory states and immune activity. [7,24,27,39-43] 
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Even so, these correlations were not adjusted for renal function, and their interpretation is 
limited.  
 
3.4.4 Mineral Bone Disease and Sodium 
The existence of non-osmotic sodium storage in osseous tissue has been known since the 
1950s. [44-47] Even so, previous studies of 23Na in humans have not looked at osseous tissue - 
due to the assumption that this 23Na reservoir is less responsive to acute physiological and 
pathological changes. [48-49] Yet, CKD is a chronic process, allowing for 23Na equilibration 
across the multiple 23Na compartments. Furthermore, CKD patients often have altered mineral 
bone physiology due to mineral bone disease and increased bone turnover (except in patients 
with adynamic bone disease). [50-51] The presence of mineral bone disease (MBD) (and its 
variations) make bone 23Na levels in this population a clinically relevant outcome.  
In our study, we found that biomarkers of MBD had significant associations, not only 
with 23Na deposition in the tibia, but also with non-osmotic 23Na in the skin and muscle (Table 3-
2). These associations persisted for soleus and tibia 23Na even after adjusting for other 
confounders (Table 3-3).  These associations can be explained by the existence of multiple 
sodium-dependent phosphate transporters in bone, renal and intestinal tissues, which are 
regulated by the parathyroid hormone, 1,25-dihidroxy-Vitamin D and fibroblast growth factor 
23. [52-53] Thus, sodium and phosphate homeostasis are closely intertwined, and MBD markers 
may have a role in 23Na deposition in tissues. Whether sodium levels in the bones is affected by 
the degree of mineral bone disease, or CKD level is still unclear.   
 
3.4.5 Cardiopulmonary System and Sodium  
CKD patients have high rates of cardiovascular mortality. [54-55] The correlation of skin 
3Na and cardiac findings in patients with CKD has been previously looked at by Schneider et al. 
[14] This group demonstrated that 23Na in the skin of 99 patients with CKD stages 1-3 was 
associated with MRI evidence of left ventricular hypertrophy. [14] In our study, we used 
troponin T as a surrogate marker of cardiovascular health, since troponitis has often been 
associated with worse prognosis in CKD. [56-60] Increased troponin T levels were associated 
with higher non-osmotic 23Na in all regions studied (Table 3-2), suggesting that 23Na 
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accumulation may play a role in end-organ damage; potentially via its immune-modulating 
effects. [24,39-43] However, these associations were not statistically significant in our regression 
models. As such, based on current evidence, no clear conclusions can be derived on the link of 
tissue 23Na and serum troponin T levels.  
Primary and secondary hypertension (another cardiovascular risk factor) has often been 
associated with increased skin and muscle 23Na in non-CKD patients. [8,9,26,61] In contrast, in 
patients with mild CKD (Stage 1-3), Schneider et al. only demonstrated a trend of higher skin 
23Na and hypertension, which did not reach statistical significance (p-value 0.07). [14] Our data 
shows a similar (albeit statistically significant) association between the clinical diagnosis of 
hypertension in CKD and 23Na levels in the posterior-leg skin, soleus and tibia. Even so, we did 
not adjust for renal function and other potential confounders.  
The association between COPD and sodium deposition in the posterior leg skin was an 
unexpected finding. We postulate four different hypotheses that may explain it. First. since 
patients with COPD have a significant history of smoking, and fat-soluble toxins can be stored in 
subcutaneous fat, this pro-inflammatory milieu may be responsible for the increased 23Na skin 
content.  Even so, no correlation was found between current or previous smoking history (latter 
defined as 20 pack-years or more) and tissue 23Na (data not shown).  Second, dialysis and CKD 
patients may have pulmonary edema which is misdiagnosis as COPD. [62] Increased pulmonary 
edema would suggest a sodium abundance and an increase use of non-osmotic sodium buffers. 
Third, sodium deposition may also occur in the airways of the respiratory system – causing 
inflammation and hyper-reactivity, which in the CKD population may be labelled as COPD. [62] 
Fourth, this finding could be secondary to chance (given the p-value of 0.05), or other types of 
bias.  
Sodium deposition in the skin, muscle and bone has the potential to provide significant 
clinical information on different organ systems due to its many associations (be they a result of 
cause, consequence or confounding). More studies will be needed to unlock the full potential of 
this novel measurement. 
 
3.4.6 Inter and Intra – Tissue Differences  
Another important finding from our pilot study is that the 23Na levels in each tissue 
appear to be associated with a unique combination of parameters. This finding is outlined in the 
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different parameters in the regression models in Table 2-3. While alterations in tibia and soleus 
23Na can be affected by albumin and PTH levels, these two parameters do not have a statistically 
significant effect on skin 23Na. Bone and muscle 23Na levels appear to have a stronger link with 
inflammatory and MBD markers, as evidenced by the higher correlation coefficients and lower 
p-values. Conversely, diabetes mellitus was found to only play a role in skin 23Na.  
Differences between tissues has been previously documented by Schneider et al. who 
found that skin but not muscle 23Na was associated with left ventricular hypertrophy. [14] In 
addition, Wang et al. showed that men have higher accumulation of 23Na in the skin vs muscle, 
while for women 23Na accumulation has the opposite pattern. [15] In contrast, a number of other 
studies have demonstrated that skin and muscle 23Na are similarly affected by diabetes mellitus, 
age, vascular endothelial growth factor levels, end-stage kidney disease, hyperaldosteronism and 
hypertension. [8,9,12,63] Compared to these latter studies, our study included a more extensive 
test for correlations between the 23Na levels of the tissues and a variety of parameters. 
Furthermore, the previous studies’ populations varied significantly, from healthy individuals and 
hypertensive patients, to patients on hemodialysis. 
Our study is also unique in highlighting the heterogeneity of 23Na deposition in skin. This 
heterogeneity can be qualitatively discerned with the naked eye (Fig. 3-4). Accounting for this 
effect, we intentionally looked at two different skin regions (pretibial skin and posterior leg 
skin), and the correlations between the 23Na in these two regions with other parameters were 
quite variable (Table 3-2 and 3-3). In general, post-leg skin associations tended to be more 
statistically robust; e.g. hypertension was significantly associated with an increase in posterior 
leg skin 23Na (correlation coefficient 0.547, p-value <0.001), but not with pretibial skin 23Na 
(correlation coefficient 0.219, p-value 0.548). Such a wide difference in p-values suggest a true 
divergence, as opposed to a measurement error or a statistical accident.  
Skin heterogeneity has not been reported in previous studies, the majority of which do 
not indicate if the 23Na signal corresponds to a specific skin region. [8-10,14-15,22,64] Similar to 
this work, in their study, Kopp et al.63 used the posterior leg skin in their measurements. Even so, 
expanded studies are needed to elucidate both the local factors in tissue 23Na storage and the 
sodium signal (either the average signal or the one from a specific skin region) that best 
corresponds to clinically significant outcomes.  
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These inter and intra-tissue divergences alludes to the existence of both macro and micro-
environmental factors that likely play a role in the regulation of non-osmotic sodium storage - 
via alterations in the GAG components of the extracellular matrix. [18-20] Potential factors 
include local dysregulation, inflammation and ischemia. [7,13,24,27,41-42] 
 
3.4.7 Limitations 
Our study did have several limitations. Since it was a cross-sectional observational study, 
causality effects cannot be determined. Measured and unmeasured confounding factors could be 
responsible for the differences in sodium levels of tissues, as well as the associations detected. 
Furthermore, we did not adjust for kidney function in our assessment of these associations.  
As a pilot study, the number of subjects in our study groups was relatively modest 
(ranging from 10 to 23). Thus, generalizability of our data to all severe CKD patients should be 
done cautiously until larger studies can be conducted. Even so, several statistically-robust 
associations were discovered, despite the small sample size, adding validity to our results. 
 
3.4.8 Discussion and Conclusions 
In our study, we observed that dialysis patients had significantly higher 23Na level in their 
skin, muscle and bone tissues compared to controls with normal kidney function. Even CKD 
patients (not on dialysis) had evidence of sodium accumulation - albeit not always statistically 
significant. No significant difference was found in the tissue 23Na levels of HD, PD and CKD 
groups. These levels correlated strongly with markers of mineral bone disease and inflammation, 
while the effect of age and sex seemed relatively limited. Yet, associated factors appeared to be 
tissue specific. More studies are needed to elucidate the effect and clinical utility of non-osmotic 
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Chapter 4  
4 Conclusions and Future Work 
This chapter contains a summary of the achievements in this thesis, as well as the 
limitations of this research. Furthermore, future directions of research will be explored.  
 
4.1 Discussion 
4.1.1 Summary of Thesis Work 
Our study investigated non-osmotic tissue sodium levels in patients with different 
severity of kidney disease (CKD, PD and HD) compared to controls. The results indicated that 
patients on dialysis have statistically higher sodium levels in all three tissues: skin, bone and 
muscle. No difference was detected between subjects with CKD (not on dialysis) and subjects on 
dialysis, and CKD patients also showed trends toward sodium accumulation – albeit not always 
statistically significant, relative to controls. 
Furthermore, we studied the associations between tissue sodium and previously 
recognized clinical factors in non-osmotic sodium build-up (see Chapter 2), as well as other 
complications of kidney disease. We did find significant correlations with inflammatory markers 
and mineral bone disease. The correlations with specific factors were found to be tissue specific: 
soleus and tibial sodium was strongly correlated with mineral bone disease and inflammatory 
markers, while skin sodium was better correlated with hypertension.  
The main contribution of this study to the existing literature is additional information in 
the evolving field of non-osmotic sodium storage. The study adds to the current knowledge of 
NO-Na specifically in renal patients. Previous literature has looked at patients with mild to 
moderate levels of CKD and acute or chronic patients on hemodialysis. [1-3] Yet, our study is 
the first to report on patients with CKD 4-5 and on peritoneal dialysis. PD patients are often 
healthier than HD patients, due to the inherent independence required by this modality. Yet, 
despite our initial hypothesis that PD patients would have lower levels of tissue sodium because 
of their preserved residual renal function, no significant difference was observed based on 
dialysis modality. No statistically significant difference was observed in tissue sodium between 
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CKD and dialysis patients, either. Even so, there was a trend of lower sodium in CKD patients, 
which may reach statistical significance with larger sample sizes.  
Similar to previous studies, we did find an association with CKD and increased tissue 
sodium. Yet, due to the observational nature of the study, causes or consequences cannot be 
ascertained.   
Our methodology was similar to those of previous studies – namely utilizing 23Na MRI 
technology to measure absolute sodium content. [4,5] This study does not help distinguish intra-
cellular vs extra-cellular sodium, or bound vs unbound states. The 23Na MRI pulse sequences 
detected sodium density levels. Even so, we do report on sodium levels in the tibia (osseous and 
bone marrow tissue) – as well as the previously reported muscle and skin tissue. Osseous sodium 
content measured with 23Na MRI technology has not been previously described. Yet, given the 
physiology and the principles underlying this technology, we have no reason to suspect that 
sodium measurements in bone would be inaccurate.       
This study also highlights the heterogeneity of non-osmotic sodium storage, both inter 
and intra-tissue. This finding is in keeping with the current view in the literature of an adaptable 
non-osmotic sodium reservoir based on glycosaminoglycan content. [6,7] Many different factors 
including the immune system, structural abnormalities, and ischemia (refer to section 2.5) could 
play a role in the micro-environment and regulate the capacity of this storage system. 
Furthermore, differences between sodium levels in the skin and muscle tissues has been 
previously noted. [1,8] The results from our study indicate that biochemical factors affecting 
sodium storage may be tissue-dependent - a relatively novel hypothesis. 
Since this study looked at clinically significant markers – including laboratory markers 
and baseline characteristics, it highlights some of the possible interactions between non-osmotic 
sodium and these clinical factors in the study population. These association are hypothesis-
generating and may direct further investigations to shed light into the pathophysiology and 
consequences of non-osmotic sodium storage.  In accordance with the published literature, which 
show an interdependent relationship between sodium and immune activation, [9-12] a link was 
demonstrated between inflammatory markers and sodium levels. Similar associations were found 
with markers of cardiovascular disease and bone mineral disease. 
In current literature, osseous storage of sodium is believed to be more static. [13] Yet, 
due to the chronicity of CKD and dialysis, in our study, sodium stores in the tibia were also 
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noticed to be higher than controls. This fact could be explained by the increased metabolic 
activity of bone in CKD, due to mineral bone disease. Even so, our ability to perturb this osseous 
compartment with current treatments (diuretics or dialysis) is unclear. Similarly, more studies 
will be needed to assess the effect of treatments in sodium levels in the skin and muscle.  
Our study highlighted clinical correlations of non-osmotic sodium in patients with kidney disease 
and adds to the current body of knowledge. Yet, more studies will be needed to understand 
sodium metabolism and use it for diagnostic and therapeutic purposes in the future. 
 
4.1.2 Study Limitations 
This study also had several limitations. First, this was a pilot study, and as such, the study 
populations (Control, CKD, HD and PD) were relatively small – maximum of 13 subjects for 
HD. These population sizes make generalization of the results to all patients with CKD a 
cautious endeavor. Furthermore, the control group did have some comorbidities (for e.g. diabetes 
mellitus and hypertension), which do affect sodium metabolism and sodium deposition 
(potentially decreasing the measured effect from kidney function). While it is reassuring that 
statistically significant trends were detectable even with these sizes and a control group that was 
not completely healthy, these results need to be demonstrated in larger clinical trials. As a pilot 
study, the purpose of this research was to roughly test the validity of our hypothesis, before more 
resource-intensive studies are undertaken. Large studies would be quite financially burdensome – 
since MRI technology is a relatively expensive imaging modality.  
Second, certain aspects of our methodology could be strengthened. The power of the 
study could have been increased by having completely healthy controls, or sex and age -
matching the control group to the patient groups. In addition, our assessment of osseous sodium 
levels included the bone marrow tissue. As such, the sodium signal detected consists of the 
average from both these tissues. Ideally these two tissues should be looked at separately, in 
future studies. Furthermore, when estimating the kidney function of dialysis patients, instead of 
using creatinine and eGFR, a more appropriate measure, such as the average of urea and 
creatinine clearances (from 24hour urine collections) could be used. Also, the associations and 
regression models between tissue sodium and other parameters did not adjust for potential 
confounding factors. As such, in future studies, more detailed statistical analysis will be 
necessary to try and assess the main parameters that play a role in tissue sodium.  
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Thirdly, as an observational study, this research has the inherent limitations of this genre 
of research. Primarily, causality cannot be established, and only associations (prone to 
confounding factors) can be generated. Randomized control trials would be the ideal study for 
showing causality, but unfortunately, these studies would be challenging and unethical to 
perform in humans in clinical settings. A proper randomized trial would require randomizing 
individuals to different levels of CKD, and then measuring sodium levels in the tissues – an 
unethical process given the high burden of morbidity which would be carried by participants.  
Fourthly, similar to other clinical studies, sampling error in the population induces further 
bias. The patient population willing to participate in clinical studies tends to often be 
compromised of healthier individuals with the capacity to give consent and travel to the research 
facility. For e.g., since for our specific study participants needed to be able to lie flat for one hour 
in the MRI scanner, CKD patients with severe pulmonary edema (likely from salt and fluid 
overload) could not participate. Also, having age and sex matched healthy controls may have 
increased the power of the study (as mentioned above). The controls were chosen with the aim of 
expediency given this was a pilot study. Even so, the participant requirements in our study were 
relatively not cumbersome, and low risk. As such, we do not suspect a significant selection bias.    
Lastly, our study methodology did not include measuring sodium content with previously 
used gold standard techniques, and we did not assess tissue water content. Unfortunately, gold-
standard sodium measurements tend to be relatively invasive (requiring tissue biopsies) or 
exposures to radiation. [4,14-18] Both of these properties often deter subjects from study 
participation. Furthermore, since multiple previous studies have validated sodium MRI 
measurements against these gold-standards, [4,19,20] we opted to avoid further undue risks 
imposed on the study population. On the other hand, we also did not assess tissue water content, 
since previous studies [21] have demonstrated that sodium accumulation exceeds water 
increases. Since in this pilot study, our MRI scan time was already 1 hour long – in the setting of 
multiple measurements averaged to increase SNR for sodium measurements, adding sequences 
to measure water content would have increased scan time. More robust investigations should be 





4.2 Future Work 
This section focuses on the future work and other areas that need to be further explored to 
expand our understanding and knowledge of sodium accumulation in CKD patients.  
 
4.2.1 Cohort Expansion and Clinical Utility  
In order to learn more about the effect of kidney function on the sodium deposition in the 
tissues, larger studies are needed that include patients with all the different stages of CKD (1-
5D), and with larger population sizes. As mentioned in Section 1.4.2, the methodology of the 
study could also be improved by ensuring the control group is completely healthy, or age, sex, 
BMI-matched controls to the patient groups. Furthermore, more detailed statistical and image 
analysis could help assess for confounding factors and differentiate between osseous and bone 
marrow sodium levels. 24hour urine collections can be used to better estimate the residual renal 
function in dialysis patients. Future studies could also include patients on home hemodialysis or 
those who have received a renal allograft (both populations have yet to be studied). Since CKD 
is a big umbrella term for several different pathophysiological mechanisms of injury in the 
kidney, the effect of the etiology of CKD, and its unique pattern of injury, on sodium 
accumulation should also be explored. Similarly, acute kidney injury can also result in severe 
impairment – sometimes requiring renal replacement therapy. This type of injury has also been 
shown to result in sodium accumulation and needs to be studied further. [3] In addition, the 
ability of our current treatments (medical or dialysis) to affect the different tissue sodium 
reservoirs also will need to be studied further. Lastly, the clinical relevance of sodium 
accumulation will need to be explored in future studies (including causes and consequences).  
All this information could be utilized clinically to direct CKD patient treatments and provide 
information on their prognosis. For e.g., dialysis treatments can be individualized to patients’ 
sodium accumulation patters – by better understanding a patient’s intrinsic pattern of sodium 
accumulation and how dialysis alters this pattern.  
 
4.2.2 Mechanistic Work 
As mentioned above, clinical observational studies cannot prove causality, limiting their 
scientific potential. Thus, further studies are required - using animal models to determine the 
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direct effect of kidney function (and the different dialysis modalities) on sodium accumulation in 
the tissues. Furthermore, while some studies have already explored the mechanisms governing 
this sodium accumulation (Section 1.5), more information is needed to assess if these 
mechanisms are altered by the uremic toxin-rich environment present in CKD (especially in 
severe stages). These studies will need to cover a broad spectrum: from cellular-level studies 
assessing the effect of cellular signaling pathways, to clinical studies looking at the effect of 
dialysis modalities on tissue sodium fluctuations.  
 
4.2.3 Technological Advancement  
In addition, sodium MRI technology is still relatively limited. Due to its low signal-to-
noise ratio, large period of scan time is dedicated to obtain limited information on a sample of 
the anatomy (in this study, a single axial slice of the lower leg). Further advancement in this 
imaging technology is required to increase SNR and decrease scan time, so that 3-dimensional 
anatomical images can be obtained. Such advancement could include using a stronger external 
magnetic field (for e.g. 7T MRI), and improving the sequences to shorten acquisition time.  
As mentioned in Section 2.4.6, it is incorrect to assume homogeneity of sodium 
accumulation in all areas of the skin, likely from the role of the micro-environment in regulating 
sodium storage. As such, more complete images may help identify specific patterns of sodium 
storage across different tissues, which may be further associated with both healthy and diseased 
states. Ideally, 23Na-MRI will become an additional imaging tool in routine clinical use (as 






This thesis was a pilot observational study measuring non-osmotic sodium storage in 
tissues of CKD patients (stages 4-5, HD and PD) compared to controls with normal kidney 
function, using non-invasive 23Na MRI technology. We observed that dialysis patients had 
significantly higher 23Na level in all tissues studied: skin, muscle and bone, compared to 
controls. No statistically significant difference was noted between the three different patient 
groups (CKD, HD and PD), despite different levels or residual renal function. Even CKD 
participants had evidence of sodium accumulation - albeit not always statistically significant. 
Yet, there was a trend of lower sodium levels in CKD participants compared to dialysis ones. 
Sodium levels were also correlated with different markers of CKD and other factors 
previously known to be associated with higher non-osmotic sodium storage. Soleus and tibia 
sodium levels were strongly associated with markers of mineral bone disease and inflammation, 
while the effect of age and sex was relatively limited. Even so, significant inter and intra-tissue 
heterogeneity was observed, and associated factors appeared to be tissue specific. This finding 
points toward an adaptable non-osmotic sodium compartment that can be influenced by local and 
global factors.  
This study is the first to look at patients on peritoneal dialysis and severe CKD (stages 4-
5), in addition to HD patients. Furthermore, it used 23Na MRI to assess multiple tissues, 
including the osseous compartment, which has not been previously reported. Our findings add to 
our current understanding of non-osmotic sodium, particularly in the relatively sodium-abundant 
CKD states, while also generating hypothesis for future studies.  
Non-osmotic sodium measured non-invasively with MRI technology has a lot of potential 
for diagnostic, therapeutic and prognostic applications. Yet, more studies are needed for 
technological advancement and to better understand sodium metabolism and storage, its causes 
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